PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26005563-6	2015	Modeling of compound 10 in the active site of HDAC2 demonstrates that the 2-(oxazol-2-yl)phenol moiety has a zinc-binding pattern similar to benzamide HDAC inhibitors.	benzamide	141-150	histone deacetylase 2	Homo sapiens	46-51
25893048-0	2015	Novel benzamide-based histamine h3 receptor antagonists: the identification of two candidates for clinical development.	benzamide	6-15	histamine receptor H3	Homo sapiens	22-43
25515955-0	2015	Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.	benzamide	107-116	sirtuin 2	Homo sapiens	71-80
25402753-8	2015	Structure-function studies determined that disruption of Hsp90alpha/Aha1 association and inhibition of cell migration correlated with the presence of a benzamide side chain, since an acetamide substituted analog was less effective.	benzamide	152-161	heat shock protein 90 alpha family class A member 1	Homo sapiens	57-67
25402753-8	2015	Structure-function studies determined that disruption of Hsp90alpha/Aha1 association and inhibition of cell migration correlated with the presence of a benzamide side chain, since an acetamide substituted analog was less effective.	benzamide	152-161	activator of HSP90 ATPase activity 1	Homo sapiens	68-72
25515955-0	2015	Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.	benzamide	107-116	sirtuin 2	Homo sapiens	82-87
25515955-2	2015	We designed and synthesized a series of benzamide derivatives as SIRT2 inhibitor candidates.	benzamide	40-49	sirtuin 2	Homo sapiens	65-70
26282548-4	2015	Chidamide, a novel benzamide-type selectively HDAC inhibitor, has been reported to induce G1 arrest and apoptosis in the relatively mature progenitor population, whereas its effect on primitive LSCs has not been clarified.	benzamide	19-28	histone deacetylase 9	Homo sapiens	46-50
25115329-0	2014	Phenyl amide linker improves the pharmacokinetics and pharmacodynamics of N-terminally mono-PEGylated human growth hormone.	benzamide	0-12	growth hormone 1	Homo sapiens	108-122
25262942-3	2014	In this study, we further explored SAR through a combination of traditional medicinal chemistry and structure-based drug design, resulting in a novel scaffold (benzamide) with selectivity against protein kinases.	benzamide	160-169	sarcosine dehydrogenase	Homo sapiens	35-38
25360823-4	2014	For HDAC1/2/3 selective-inhibitor benzamide, the conserved tyrosine could modulate the coordinative ability of the central atom (Zn(2+)), while for pan-inhibitor SAHA, the conserved tyrosine could increase the chelating ability of the ligand (SAHA).	benzamide	34-43	histone deacetylase 1	Homo sapiens	4-13
24559867-4	2014	The phenyl amide disila compound 22 showed the most potent ROR-inhibitory activity among the compounds examined.	benzamide	4-16	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	59-62
24721323-2	2014	Chidamide is a novel benzamide chemical class of HDAC inhibitor that selectively inhibited HDAC1, 2, 3 and 10.	benzamide	21-30	histone deacetylase 1	Homo sapiens	91-109
24638994-4	2014	In human ether-a-go-go-related gene 1 (hERG1) K(+) channels, C-type inactivation is allosterically inhibited by ICA-105574, a substituted benzamide.	benzamide	138-147	potassium voltage-gated channel subfamily H member 2	Homo sapiens	39-44
24878359-9	2014	These findings strongly support our assumption that the fragment of benzamide can replace the pyridine ring in some PI3K and mTOR dual inhibitor to design novel anticancer agents.	benzamide	68-77	mechanistic target of rapamycin kinase	Homo sapiens	125-129
24789078-2	2014	Removal of the benzamide group of the intermediates could furnish chiral C-1 substituted tetrahydroisoquinolines (see scheme) in high yields and excellent stereoselectivities.	benzamide	15-24	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	73-76
24900823-0	2014	Phenyl carboxamide analogues as spleen tyrosine kinase (syk) inhibitors.	benzamide	0-18	spleen associated tyrosine kinase	Homo sapiens	56-59
24881658-1	2014	Synthesis and structure-activity relationship of a novel series of isoquinoline CRTH2 antagonists bearing a methylene linker between the isoquinoline and benzamide moieties were described.	benzamide	154-163	prostaglandin D2 receptor 2	Cavia porcellus	80-85
24405209-9	2014	The intermediacy of an alkyl radical was evidenced by the catalytic reaction of cyclohexane with benzamide in the presence of CBr4, which formed exclusively bromocyclohexane.	benzamide	97-106	carbonyl reductase 4	Homo sapiens	126-130
23757208-2	2013	We exploited knowledge on nAChR ligands and their binding site that were previously identified by our laboratory through virtual screenings and identified benzamide analogs as a novel chemical class of neuronal nicotinic receptor (nAChR) ligands.	benzamide	155-164	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	26-31
25450624-3	2014	In vitro enzymatic assay at 10 microM against all the eight human PI3K isoforms showed that an unsubstituted benzamide group at position 6 and an acetyl group at N(4) gave the best inhibitory activity on PI3Kgamma.	benzamide	109-118	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Homo sapiens	204-213
25254219-2	2014	A 18F-labeled benzamide derivative, [18F]N-(2-diethylaminoethyl)-4-[2-(2-(2-fluoroethoxy) ethoxy)ethoxy]benzamide ([18F]FPBZA), was developed as a promising PET probe for primary and metastatic melanoma.	benzamide	14-23	thyroid stimulating hormone receptor	Mus musculus	157-160
24256509-2	2013	Arylation was accomplished using either Ni(COD)2 or 1,10-phenanthroline in substoichiometric amounts, and the reaction conditions were applied to a variety of electronically differentiated benzamide substrates.	benzamide	189-198	COD2	Homo sapiens	43-48
23757208-2	2013	We exploited knowledge on nAChR ligands and their binding site that were previously identified by our laboratory through virtual screenings and identified benzamide analogs as a novel chemical class of neuronal nicotinic receptor (nAChR) ligands.	benzamide	155-164	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	231-236
23333209-1	2013	AX10479, the phenyl amide of 4-hydroxy-8-methanesulfonylamino-quinoline-2-carboxylic acid, was identified as a Zn(2+)-dependent, 27nM inhibitor of human plasma Lp-PLA(2).	benzamide	13-25	phospholipase A2 group VII	Homo sapiens	160-168
23652817-3	2013	Using suitable proxies arranged in pseudo-crystalline setups we discriminate the contribution of hydrogen bonding, pi-pi interactions and intra-molecular interactions to the lattice energies of the most relevant (P1 and P3) benzamide polymorphs.	benzamide	224-233	crystallin gamma F, pseudogene	Homo sapiens	213-222
23656327-4	2013	Specifically, a subset of compounds bearing phenyl and substituted phenyl carboxamides induced lower IL-6 release while maintaining higher IP-10 production, skewing toward the type I interferon pathway.	benzamide	67-86	interleukin 6	Homo sapiens	101-105
23656327-4	2013	Specifically, a subset of compounds bearing phenyl and substituted phenyl carboxamides induced lower IL-6 release while maintaining higher IP-10 production, skewing toward the type I interferon pathway.	benzamide	67-86	C-X-C motif chemokine ligand 10	Homo sapiens	139-144
23218712-1	2013	Novel benzamide derivatives were synthesized and tested at in vitro assay by measuring fold increase of glucokinase activity at 5.0 mM glucose concentration.	benzamide	6-15	glucokinase	Mus musculus	104-115
23380375-2	2013	Optimization of the benzamide and central ring components of the core scaffold led to the identification of a GlyT-1 inhibitor that demonstrated in vivo activity in a rodent cerebral spinal fluid (CSF) glycine model.	benzamide	20-29	solute carrier family 6 member 9	Homo sapiens	110-116
22588261-0	2012	Ring substituents on substituted benzamide ligands indirectly mediate interactions with position 7.39 of transmembrane helix 7 of the D4 dopamine receptor.	benzamide	33-42	dopamine receptor D4	Homo sapiens	134-154
23042668-2	2012	Here, lead optimization of H(3)R inverse agonists bearing a thiazolo[5,4-c]piperidine group gave rise to a clinical candidate with a much simpler unprecedented benzamide scaffold, displaying decreased hERG activity while maintaining high brain receptor occupancies.	benzamide	160-169	ETS transcription factor ERG	Homo sapiens	201-205
22818799-0	2012	Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.	benzamide	80-89	histone deacetylase 2	Homo sapiens	97-124
22818799-3	2012	More complex second generation HDACIs undergoing clinical trials, such as the benzamide group compounds MS-275 and MGCD0103, are specific primarily for HDAC1 and HDAC2.	benzamide	78-87	histone deacetylase 1	Homo sapiens	152-157
22818799-3	2012	More complex second generation HDACIs undergoing clinical trials, such as the benzamide group compounds MS-275 and MGCD0103, are specific primarily for HDAC1 and HDAC2.	benzamide	78-87	histone deacetylase 2	Homo sapiens	162-167
23123015-0	2012	Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors.	benzamide	83-92	kinase insert domain receptor	Homo sapiens	107-113
23263798-3	2012	Novel benzamide derivatives were synthesized and tested using in vitro assays by measuring fold increase of glucokinase activity at 5.0 mM glucose concentration.	benzamide	6-15	glucokinase	Mus musculus	108-119
22939233-0	2012	Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.	benzamide	18-27	C-C motif chemokine receptor 2	Homo sapiens	66-89
22939233-0	2012	Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.	benzamide	18-27	C-C motif chemokine receptor 2	Homo sapiens	91-95
22771007-0	2012	Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.	benzamide	119-128	histone deacetylase 2	Homo sapiens	140-161
22459213-1	2012	A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described.	benzamide	12-21	sarcosinemia autosomal recessive	Mus musculus	115-118
22396044-0	2012	A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-kappaB activity: a potential osteoclastogenesis inhibitor for experimental arthritis.	benzamide	2-11	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	51-57
22396044-0	2012	A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-kappaB activity: a potential osteoclastogenesis inhibitor for experimental arthritis.	benzamide	2-11	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	62-71
22217870-1	2012	AX10185, the phenyl amide of xanthurenic acid, was found to be a sub-100nM inhibitor of Lp-PLA(2).	benzamide	13-25	phospholipase A2 group VII	Homo sapiens	88-96
22277094-3	2012	Benzoyl 6 and benzamide 17 are the most selective compounds toward 17beta-HSD2 described so far.	benzamide	14-23	hydroxysteroid 17-beta dehydrogenase 2	Homo sapiens	67-78
21507637-1	2011	Seeking compounds preferentially potent and selective for MMP-13, we reported in the preceding Letter on a series of hydroxamic acids with a flexible benzamide tail groups.	benzamide	150-159	matrix metallopeptidase 13	Rattus norvegicus	58-64
21858617-0	2011	A benzamide-linked small molecule HS-Cf inhibits TNF-alpha-induced interferon regulatory factor-1 in porcine chondrocytes: a potential disease-modifying drug for osteoarthritis therapeutics.	benzamide	2-11	tumor necrosis factor	Sus scrofa	49-58
21858617-0	2011	A benzamide-linked small molecule HS-Cf inhibits TNF-alpha-induced interferon regulatory factor-1 in porcine chondrocytes: a potential disease-modifying drug for osteoarthritis therapeutics.	benzamide	2-11	interferon regulatory factor 1	Sus scrofa	67-97
21858617-8	2011	RESULTS: Bioassay screening of benzamide-linked small molecules revealed that 2-hydroxy-N-[3-(trifluoromethyl)phenyl]benzamide (HS-Cf) was a potent inhibitor of NO production and iNOS expression in TNF-alpha-stimulated porcine chondrocytes.	benzamide	31-40	LOC396821	Sus scrofa	179-183
21858617-8	2011	RESULTS: Bioassay screening of benzamide-linked small molecules revealed that 2-hydroxy-N-[3-(trifluoromethyl)phenyl]benzamide (HS-Cf) was a potent inhibitor of NO production and iNOS expression in TNF-alpha-stimulated porcine chondrocytes.	benzamide	31-40	tumor necrosis factor	Sus scrofa	198-207
21858617-13	2011	CONCLUSIONS: In a minilibrary containing 300 small molecules, we identified a benzamide-linked small molecule, HS-Cf, that through down-regulating TNF-alpha-induced IRF-1 activity suppressed chondrocyte activation and prevented cartilage destruction.	benzamide	78-87	tumor necrosis factor	Sus scrofa	147-156
21858617-13	2011	CONCLUSIONS: In a minilibrary containing 300 small molecules, we identified a benzamide-linked small molecule, HS-Cf, that through down-regulating TNF-alpha-induced IRF-1 activity suppressed chondrocyte activation and prevented cartilage destruction.	benzamide	78-87	interferon regulatory factor 1	Sus scrofa	165-170
21782424-1	2011	A non-estrogenic inhibitor of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) was designed based on a modified 3-hydroxy-estra-1,3,5(10)-triene core having an additional five-member lactone ring and a benzamide group.	benzamide	210-219	RNA, U1 small nuclear 1	Homo sapiens	6-85
21414780-4	2011	Increasing the acidity of the amide proton by converting the benzamide in lead 1 to an anilide provided single digit nanomolar MCHR1 antagonists while replacing the dimethoxyphenyl ring of 1 with alkyl groups possessing increased polarity dramatically reduced the hERG inhibition.	benzamide	61-70	melanin concentrating hormone receptor 1	Homo sapiens	127-132
21246737-2	2011	The design, synthesis, and functional characterisation of benzamide analogues at the 5-HT3A receptor yielded substantial information concerning the analogues as 5-HT3 receptor agonists.	benzamide	58-67	5-hydroxytryptamine receptor 3A	Homo sapiens	85-91
21316218-2	2011	Design and synthesis of a novel MEK inhibitor, based on the 3D-structural information of the target enzyme, and then multidimensional optimization including metabolic stability, physicochemical properties and safety profiles were effectively performed and led to the identification of a clinical candidate for an orally available potent MEK inhibitor, CH4987655, possessing a unique 3-oxo-oxazinane ring structure at the 5-position of the benzamide core structure.	benzamide	439-448	mitogen-activated protein kinase kinase 7	Homo sapiens	32-35
21316218-2	2011	Design and synthesis of a novel MEK inhibitor, based on the 3D-structural information of the target enzyme, and then multidimensional optimization including metabolic stability, physicochemical properties and safety profiles were effectively performed and led to the identification of a clinical candidate for an orally available potent MEK inhibitor, CH4987655, possessing a unique 3-oxo-oxazinane ring structure at the 5-position of the benzamide core structure.	benzamide	439-448	mitogen-activated protein kinase kinase 7	Homo sapiens	337-340
21904660-1	2010	Structural modifications to the coumarin core and benzamide side chain of novobiocin have successfully transformed the natural product from a selective DNA gyrase inhibitor into a potent inhibitor of the Hsp90 C-terminus.	benzamide	50-59	heat shock protein 90 alpha family class A member 1	Homo sapiens	204-209
20709754-10	2010	Flecainide docking in the Kv1.2-based homology model of Kv2.1 predicts the ligand ammonium group in the central cavity and the benzamide moiety in a niche between S6 and the P-helix.	benzamide	127-136	potassium channel, voltage gated shaker related subfamily A, member 2 L homeolog	Xenopus laevis	26-31
20709754-10	2010	Flecainide docking in the Kv1.2-based homology model of Kv2.1 predicts the ligand ammonium group in the central cavity and the benzamide moiety in a niche between S6 and the P-helix.	benzamide	127-136	potassium channel, voltage gated Shab related subfamily B, member 1 S homeolog	Xenopus laevis	56-61
20705631-3	2010	We aimed to evaluate the efficacy of benzamide, a PARP inhibitor, in an experimental model of ANP.	benzamide	37-46	poly (ADP-ribose) polymerase 1	Rattus norvegicus	50-54
20705631-13	2010	We observed that inhibition of PARP with benzamide reduced the severity, the mortality, the bacterial translocation rates and the neopterin concentrations in an experimental ANP model in rats.	benzamide	41-50	poly (ADP-ribose) polymerase 1	Rattus norvegicus	31-35
20045315-1	2010	Through conformational restriction of a benzamide by formation of a seven-membered hydrogen-bond with an oxindole carbonyl group, a series of PARP inhibitors was designed for appropriate orientation for binding to the PARP surface.	benzamide	40-49	poly(ADP-ribose) polymerase 1	Homo sapiens	142-146
19998477-2	2010	Here we investigated the therapeutic effect of the PARP inhibitor benzamide against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice.	benzamide	66-75	poly (ADP-ribose) polymerase family, member 1	Mus musculus	51-55
19998477-5	2010	Furthermore, our immunohistochemical study showed that posttreatment with benzamide significantly prevented neuronal damage by suppressing overexpression of neuronal, microglial, and astroglial PARP after MPTP treatment.	benzamide	74-83	poly (ADP-ribose) polymerase family, member 1	Mus musculus	194-198
20045315-1	2010	Through conformational restriction of a benzamide by formation of a seven-membered hydrogen-bond with an oxindole carbonyl group, a series of PARP inhibitors was designed for appropriate orientation for binding to the PARP surface.	benzamide	40-49	poly(ADP-ribose) polymerase 1	Homo sapiens	218-222
19758809-0	2009	Benzamide derivatives as dual-action hypoglycemic agents that inhibit glycogen phosphorylase and activate glucokinase.	benzamide	0-9	glucokinase	Homo sapiens	106-117
19811913-2	2009	Thus, extending the length of the original benzamide side chain by a single methylene unit imparts CCK1R affinity to the series, and further fine tuning of the affinity results in CCK1R selectivity of greater than 100-fold.	benzamide	43-52	cholecystokinin A receptor	Homo sapiens	99-104
19811913-2	2009	Thus, extending the length of the original benzamide side chain by a single methylene unit imparts CCK1R affinity to the series, and further fine tuning of the affinity results in CCK1R selectivity of greater than 100-fold.	benzamide	43-52	cholecystokinin A receptor	Homo sapiens	180-185
20181479-0	2010	Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.	benzamide	27-36	adrenoceptor beta 3	Homo sapiens	73-98
20641656-15	2004	Most benzamide derivatives possess the common structure element of Ph-CONH(CH2)mNR2 (m = 1,2), and they exhibit comparable properties such as high melanoma uptake, which is a positive attribute for potentially useful imaging agents (11).	benzamide	5-14	motor neuron and pancreas homeobox 1	Mus musculus	79-83
20641666-15	2004	Most benzamide derivatives possess the common structure element of Ph-CONH(CH2)mNR2 (m = 1,2), and they exhibit comparable properties such as high melanoma uptake, which is a positive attribute for potentially useful imaging agents (12).	benzamide	5-14	motor neuron and pancreas homeobox 1	Mus musculus	79-83
19758809-1	2009	A series of benzamide derivatives which can simultaneously inhibit glycogen phosphorylase (GP) and activate glucokinase (GK) were prepared and evaluated.	benzamide	12-21	glucokinase	Homo sapiens	108-119
19758809-1	2009	A series of benzamide derivatives which can simultaneously inhibit glycogen phosphorylase (GP) and activate glucokinase (GK) were prepared and evaluated.	benzamide	12-21	glucokinase	Homo sapiens	121-123
19664921-4	2009	The piperazine ring was shown to be a critical element of the HIV-1 attachment inhibiting pharmacophore, acting as a scaffold to deploy the indole glyoxamide and benzamide in a topographical relationship that complements the binding site on gp120.	benzamide	162-171	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	241-246
19447888-6	2009	Furthermore, PARP-1 inhibitor (benzamide) decreased PARP-1 binding to G(-172) --> T without affecting mRNA or protein expression level of PARP-1 and down-regulated the subsequent MOR gene expression in SH-SY5Y cells.	benzamide	31-40	poly(ADP-ribose) polymerase 1	Homo sapiens	13-19
19447888-6	2009	Furthermore, PARP-1 inhibitor (benzamide) decreased PARP-1 binding to G(-172) --> T without affecting mRNA or protein expression level of PARP-1 and down-regulated the subsequent MOR gene expression in SH-SY5Y cells.	benzamide	31-40	poly(ADP-ribose) polymerase 1	Homo sapiens	52-58
19447888-6	2009	Furthermore, PARP-1 inhibitor (benzamide) decreased PARP-1 binding to G(-172) --> T without affecting mRNA or protein expression level of PARP-1 and down-regulated the subsequent MOR gene expression in SH-SY5Y cells.	benzamide	31-40	poly(ADP-ribose) polymerase 1	Homo sapiens	52-58
19447888-6	2009	Furthermore, PARP-1 inhibitor (benzamide) decreased PARP-1 binding to G(-172) --> T without affecting mRNA or protein expression level of PARP-1 and down-regulated the subsequent MOR gene expression in SH-SY5Y cells.	benzamide	31-40	opioid receptor mu 1	Homo sapiens	179-182
19200741-6	2009	We will present the synthesis, biological activities and SAR study of a series of pyrazolo[1,5-a]pyrimidines with an optimized phenyl amide moiety at the C-7 position.	benzamide	127-139	sarcosine dehydrogenase	Homo sapiens	57-60
19350613-1	2009	We compare three structurally different classes of histone deacetylase (HDAC) inhibitors that contain benzamide, hydroxamate, or thiol groups as the zinc binding group (ZBG) for their ability to protect cortical neurons in culture from cell death induced by oxidative stress.	benzamide	102-111	histone deacetylase 9	Homo sapiens	51-70
19350613-1	2009	We compare three structurally different classes of histone deacetylase (HDAC) inhibitors that contain benzamide, hydroxamate, or thiol groups as the zinc binding group (ZBG) for their ability to protect cortical neurons in culture from cell death induced by oxidative stress.	benzamide	102-111	histone deacetylase 9	Homo sapiens	72-76
19246196-1	2009	Benzamide 1 demonstrated good potency as a selective ITK inhibitor, however the amide moiety was found to be hydrolytically labile in vivo, resulting in low oral exposure and the generation of mutagenic aromatic amine metabolites.	benzamide	0-9	IL2 inducible T cell kinase	Homo sapiens	53-56
18155908-0	2008	Synthesis of benzamide derivatives as TRPV1 antagonists.	benzamide	13-22	transient receptor potential cation channel subfamily V member 1	Homo sapiens	38-43
18501976-1	2008	The present study is aimed at evaluating the functional and neuroprotective effect of benzamide, a poly-(ADP-ribose) polymerase (PARP) inhibitor on delayed neuronal death (DND) in hippocampus CA1 region and memory impairment following global cerebral ischemia (GCI) in a mouse model.	benzamide	86-95	poly (ADP-ribose) polymerase family, member 1	Mus musculus	99-127
18501976-1	2008	The present study is aimed at evaluating the functional and neuroprotective effect of benzamide, a poly-(ADP-ribose) polymerase (PARP) inhibitor on delayed neuronal death (DND) in hippocampus CA1 region and memory impairment following global cerebral ischemia (GCI) in a mouse model.	benzamide	86-95	poly (ADP-ribose) polymerase family, member 1	Mus musculus	129-133
18501976-1	2008	The present study is aimed at evaluating the functional and neuroprotective effect of benzamide, a poly-(ADP-ribose) polymerase (PARP) inhibitor on delayed neuronal death (DND) in hippocampus CA1 region and memory impairment following global cerebral ischemia (GCI) in a mouse model.	benzamide	86-95	carbonic anhydrase 1	Mus musculus	192-195
18501976-6	2008	It is clear from the present experiment that benzamide treatment significantly decreases the iNOS expression and number of apoptotic neurons and thereby improves the neuronal survival and memory during GCI.	benzamide	45-54	nitric oxide synthase 2, inducible	Mus musculus	93-97
18553955-0	2008	Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.	benzamide	27-36	RNA, U1 small nuclear 1	Homo sapiens	51-106
18553955-1	2008	We report the discovery of potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase (11beta-HSD1).	benzamide	34-43	hydroxysteroid 11-beta dehydrogenase 1	Homo sapiens	95-106
18695944-2	2009	Benzamide (BA) and 4-amino-1,8-naphthalimide (NAP), two well-known inhibitors of PARP, treatment increased nuclear fragmentation and caspase-3 activity in HeLa (Human cervical cancer cell line) cells.	benzamide	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	81-85
18695944-2	2009	Benzamide (BA) and 4-amino-1,8-naphthalimide (NAP), two well-known inhibitors of PARP, treatment increased nuclear fragmentation and caspase-3 activity in HeLa (Human cervical cancer cell line) cells.	benzamide	0-9	caspase 3	Homo sapiens	133-142
18695944-2	2009	Benzamide (BA) and 4-amino-1,8-naphthalimide (NAP), two well-known inhibitors of PARP, treatment increased nuclear fragmentation and caspase-3 activity in HeLa (Human cervical cancer cell line) cells.	benzamide	11-13	poly(ADP-ribose) polymerase 1	Homo sapiens	81-85
18695944-2	2009	Benzamide (BA) and 4-amino-1,8-naphthalimide (NAP), two well-known inhibitors of PARP, treatment increased nuclear fragmentation and caspase-3 activity in HeLa (Human cervical cancer cell line) cells.	benzamide	11-13	caspase 3	Homo sapiens	133-142
18695944-5	2009	PARP-1 knock down cells were sensitive to BA induced nuclear fragmentation and caspase-3 activation while exogenous expression of PARP-1 rendered cells resistant to BA induced apoptosis.	benzamide	42-44	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
18695944-5	2009	PARP-1 knock down cells were sensitive to BA induced nuclear fragmentation and caspase-3 activation while exogenous expression of PARP-1 rendered cells resistant to BA induced apoptosis.	benzamide	165-167	poly(ADP-ribose) polymerase 1	Homo sapiens	130-136
18599297-1	2008	In the investigation of the structure-activity relationship of nonpeptide AT(2) receptor agonists, a series of substituted benzamide analogues of the selective nonpeptide AT(2) receptor agonist M024 have been synthesised.	benzamide	123-132	angiotensin II receptor, type 2	Mus musculus	171-185
18155908-2	2008	Compound 1 has led to potent TRPV1 antagonistic benzamide derivatives ((+/-)-2: human IC(50)=23 nM, (+/-)-3: human IC(50)=14 nM in the capsaicin-induced calcium influx assay) containing indole and naphthyl moieties, obtained by elaboration of the tryptamine scaffold or via bioisosteric replacements.	benzamide	48-57	transient receptor potential cation channel subfamily V member 1	Homo sapiens	29-34
18673170-0	2008	Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents.	benzamide	87-96	histone deacetylase 9	Homo sapiens	0-19
17951061-4	2008	Further structural modifications of the benzamide and piperidine moieties of 1 led to the identification of exo-N-{8-[(6-fluoro-2-naphthyl)methyl]-8-azabicyclo[3.2.1]oct-3- yl}biphenyl-2-carboxamide [corrected] (31) as a potent CCR3 antagonist with an IC(50) value of 0.020 microM.	benzamide	40-49	C-C motif chemokine receptor 3	Homo sapiens	228-232
18850361-1	2008	S-3-iodo-N-(1-ethyl-2-pyrrolidinyl)methyl-2-hydroxy-6-methoxybenzamide (IBZM) is one of the several benzamide derivatives showing a high affinity for the central nervous system (CNS) D2 dopamine receptor.	benzamide	61-70	dopamine receptor D2	Rattus norvegicus	183-203
17210149-1	2007	The 1:1 inclusion complex of beta-cyclodextrin and benzamide was prepared and characterized by single crystal X-ray diffraction, PXRD, TGA, and IR.	benzamide	51-60	T-box transcription factor 1	Homo sapiens	135-138
17896912-4	2007	Since the early benzamide inhibitors of the 1980s PARP inhibitors, developed through structure-activity relationships and crystal structure-based drug design, that are 1,000 x more potent have been identified.	benzamide	16-25	poly(ADP-ribose) polymerase 1	Homo sapiens	50-54
17455259-0	2007	Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group.	benzamide	82-91	histone deacetylase 9	Homo sapiens	57-61
17728843-8	2007	These changes were prevented by the PARP inhibitors benzamide or DPQ (3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone) or PARP-1 gene deletion (PARP-1 KO).	benzamide	52-61	poly(ADP-ribose) polymerase 1	Homo sapiens	36-40
17728843-8	2007	These changes were prevented by the PARP inhibitors benzamide or DPQ (3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone) or PARP-1 gene deletion (PARP-1 KO).	benzamide	52-61	poly(ADP-ribose) polymerase 1	Homo sapiens	136-142
17728843-8	2007	These changes were prevented by the PARP inhibitors benzamide or DPQ (3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone) or PARP-1 gene deletion (PARP-1 KO).	benzamide	52-61	poly(ADP-ribose) polymerase 1	Homo sapiens	158-164
16724231-0	2006	The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.	benzamide	4-13	survival of motor neuron 2, centromeric	Homo sapiens	83-87
17169559-5	2007	Furthermore, SAR analysis suggests that steric, electronic, and lipophilic characteristics of substituents in the benzamide region of DNK333 have a crucial effect on both the NK(1) and NK(2) receptor antagonist activities.	benzamide	114-123	tachykinin receptor 2	Homo sapiens	185-199
16288681-4	2006	In this study, we measured dopamine D2 receptor occupancy of two conventional benzamide antipsychotics, sulpiride and sultopride, using positron emission tomography, to investigate the rationale of their clinical dose.	benzamide	78-87	dopamine receptor D2	Homo sapiens	27-47
16724231-6	2006	Here we show that the novel benzamide M344, an HDAC inhibitor, up-regulates SMN2 protein expression in fibroblast cells derived from SMA patients up to 7-fold after 64 h of treatment.	benzamide	28-37	survival of motor neuron 2, centromeric	Homo sapiens	76-80
17249247-0	2006	The benzamide derivative N-[1-(7-tert-Butyl-1H-indol-3-ylmethyl)-2-(4-cyclopropanecarbonyl-3-methyl-piperazin-1-yl)-2-oxo-ethyl]-4-nitro-benzamide (SP-10) reduces HIV-1 infectivity in vitro by modifying actin dynamics.	benzamide	4-13	acrosomal vesicle protein 1	Homo sapiens	148-153
16364640-4	2006	Several compounds containing bulky lipophilic substituents at the benzamide pharmacophore yielded 10- to 17-fold selectivity for the VEGFR-2 versus VEGFR-1 kinase.	benzamide	66-75	kinase insert domain receptor	Homo sapiens	133-140
16364640-4	2006	Several compounds containing bulky lipophilic substituents at the benzamide pharmacophore yielded 10- to 17-fold selectivity for the VEGFR-2 versus VEGFR-1 kinase.	benzamide	66-75	fms related receptor tyrosine kinase 1	Homo sapiens	148-155
17249247-3	2006	We investigated the in vitro efficacy, safety and mechanism of action of the benzamide derivative N-[1-(7-tert-Butyl-1H-indol-3-ylmethyl)-2-(4-cyclopropanecarbonyl-3-methyl-piperazin-1-yl)-2-oxo-ethyl]-4-nitro-benzamide (SP-10), a potential new HIV treatment.	benzamide	77-86	acrosomal vesicle protein 1	Homo sapiens	221-226
16085414-1	2005	Several potent and efficacious MCHr1 antagonists containing an ortho-amino benzamide or nicotinamide chemotype have been identified, exemplified by 28 and 50.	benzamide	75-84	melanin concentrating hormone receptor 1	Homo sapiens	31-36
16134937-2	2005	Novel 6-acylamino-2-aminoquinoline melanin-concentrating hormone 1 receptor (MCH1R) antagonists were identified by sequential in silico screening with 3D pharmacophore models derived from a series of benzamide antagonists.	benzamide	200-209	melanin concentrating hormone receptor 1	Homo sapiens	35-75
16134937-2	2005	Novel 6-acylamino-2-aminoquinoline melanin-concentrating hormone 1 receptor (MCH1R) antagonists were identified by sequential in silico screening with 3D pharmacophore models derived from a series of benzamide antagonists.	benzamide	200-209	melanin concentrating hormone receptor 1	Homo sapiens	77-82
16098204-8	2005	Further, in K562 cells, immunoprecipitation with the anti-TERT IgG and probed anti-poly (ADP-ribose) IgG revealed that TERT was poly(ADP-ribosyl)ated in the physiological condition of cell growth and such poly(ADP-ribosyl)ation was inhibited by benzamide treatment.	benzamide	245-254	telomerase reverse transcriptase	Homo sapiens	119-123
16098204-9	2005	Decrease in TEP1/TP1 expression and poly(ADP-ribosyl)ation of TERT were correlated with the inhibition of PARP activity by benzamide, indicating that PARP had a role in telomerase activity through poly(ADP-ribosyl)ation of TERT and down-regulation of TEP1/TP1.	benzamide	123-132	telomerase protein component 1	Cricetulus griseus	12-16
16098204-9	2005	Decrease in TEP1/TP1 expression and poly(ADP-ribosyl)ation of TERT were correlated with the inhibition of PARP activity by benzamide, indicating that PARP had a role in telomerase activity through poly(ADP-ribosyl)ation of TERT and down-regulation of TEP1/TP1.	benzamide	123-132	telomerase reverse transcriptase	Cricetulus griseus	62-66
16098204-9	2005	Decrease in TEP1/TP1 expression and poly(ADP-ribosyl)ation of TERT were correlated with the inhibition of PARP activity by benzamide, indicating that PARP had a role in telomerase activity through poly(ADP-ribosyl)ation of TERT and down-regulation of TEP1/TP1.	benzamide	123-132	poly [ADP-ribose] polymerase 1	Cricetulus griseus	106-110
16098204-9	2005	Decrease in TEP1/TP1 expression and poly(ADP-ribosyl)ation of TERT were correlated with the inhibition of PARP activity by benzamide, indicating that PARP had a role in telomerase activity through poly(ADP-ribosyl)ation of TERT and down-regulation of TEP1/TP1.	benzamide	123-132	poly [ADP-ribose] polymerase 1	Cricetulus griseus	150-154
15740849-4	2005	MK-801 (NMDA receptor antagonist) as well as benzamide (PARP inhibitor), MDL 28170 (calpain inhibitor) and roscovitine (cyclin-dependent kinase inhibitor) inhibited the glutamate response to the YY1 complexes.	benzamide	45-54	poly(ADP-ribose) polymerase 1	Homo sapiens	56-60
20711287-1	2005	BACKGROUND: Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA).	benzamide	27-36	monoamine oxidase A	Homo sapiens	67-86
15626725-10	2005	The regional selectivity of benzamide drugs (ampakines) may be explained, at least in part, by a lower potency at thalamic AMPA receptors, perhaps due to the prevalence of the subunits GluR3 and 4.	benzamide	28-37	glutamate ionotropic receptor AMPA type subunit 3	Homo sapiens	185-196
15950463-1	2005	The identification of a novel series of benzamide-containing MCHr1 antagonists is described.	benzamide	40-49	melanin-concentrating hormone receptor 1	Mus musculus	61-66
15740849-4	2005	MK-801 (NMDA receptor antagonist) as well as benzamide (PARP inhibitor), MDL 28170 (calpain inhibitor) and roscovitine (cyclin-dependent kinase inhibitor) inhibited the glutamate response to the YY1 complexes.	benzamide	45-54	YY1 transcription factor	Homo sapiens	195-198
16036766-5	2005	In the present paper the authors present their results using another benzamide with weak cholinesterase inhibitory properties, tiapride (TIA).	benzamide	69-78	butyrylcholinesterase	Homo sapiens	89-103
16178729-5	2005	The original compound in the benzamide series was discovered from screening and this series was optimized using an iterative library synthesis approach to explore SAR in each of three regions of the molecule.	benzamide	29-38	sarcosine dehydrogenase	Homo sapiens	163-166
16178729-7	2005	The pyrazole series used a fragment library approach based on small structural motives from the benzamide series to discover lead compounds and establish SAR.	benzamide	96-105	sarcosine dehydrogenase	Homo sapiens	154-157
15186837-4	2004	According to the docking simulation using the X-ray structure of EGFR kinase domain in complex with erlotinib, the LigScore2 scoring function value of erlotinib was calculated as 5.61, whereas that of the benzamide 1c was 5.05.	benzamide	205-214	epidermal growth factor receptor	Homo sapiens	65-69
15300712-1	2004	The benzamide compound metoclopramide (MCP) protects against cholinesterase inhibition by paraoxon (POX) both in vitro and in vivo.	benzamide	4-13	butyrylcholinesterase	Rattus norvegicus	61-75
15589979-12	2005	Finally, the PARP inhibitors benzamide and 6(5H)-phenanthridinone exerted notable inhibition of PARP activity and the nuclear translocation of the mitochondrial protein AIF (apoptosis-inducing factor) in MNNG-treated cells; however, these compounds exhibited no detectable inhibitory effects on MNNG-induced death in human lymphoblastoid cells.	benzamide	29-38	poly(ADP-ribose) polymerase 1	Homo sapiens	13-17
15589979-12	2005	Finally, the PARP inhibitors benzamide and 6(5H)-phenanthridinone exerted notable inhibition of PARP activity and the nuclear translocation of the mitochondrial protein AIF (apoptosis-inducing factor) in MNNG-treated cells; however, these compounds exhibited no detectable inhibitory effects on MNNG-induced death in human lymphoblastoid cells.	benzamide	29-38	poly(ADP-ribose) polymerase 1	Homo sapiens	96-100
15591342-4	2004	Moreover, embryonic trophoblast stem cell lines established from early PARG null embryos are viable only when cultured in medium containing the poly(ADP-ribose) polymerase inhibitor benzamide.	benzamide	182-191	poly (ADP-ribose) glycohydrolase	Mus musculus	71-75
15591342-4	2004	Moreover, embryonic trophoblast stem cell lines established from early PARG null embryos are viable only when cultured in medium containing the poly(ADP-ribose) polymerase inhibitor benzamide.	benzamide	182-191	poly (ADP-ribose) polymerase family, member 1	Mus musculus	144-171
15591342-5	2004	Cells lacking PARG also show reduced growth, accumulation of PAR, and increased sensitivity to cytotoxicity induced by N-methyl-N"-nitro-N-nitrosoguanidine and menadione after benzamide withdrawal.	benzamide	176-185	poly (ADP-ribose) glycohydrolase	Mus musculus	14-18
15450410-1	2004	To investigate the effect of benzamide and nicotinamide, well known inhibitors of poly(ADP-ribose) polymerase, in Chinese hamster V79 cells at the physiological condition of cell growth, we have tested the ability of the inhibitors to induce apoptosis.	benzamide	29-38	poly [ADP-ribose] polymerase 1	Cricetulus griseus	82-109
15450410-5	2004	However, 5 mM benzamide pre-treatment inhibited the nucleosomal ladders induced by gamma-irradiation indicating the role of poly(ADP-ribose) polymerase was different in irradiated cells and in un-irradiated cells.	benzamide	14-23	poly [ADP-ribose] polymerase 1	Cricetulus griseus	124-151
14718597-4	2004	Structural analysis of one compound, a benzamide derivative, led to the identification of four related molecules, which are also OPG inducers.	benzamide	39-48	TNF receptor superfamily member 11B	Rattus norvegicus	129-132
14670625-0	2004	The PARP inhibitor benzamide protects against kainate and NMDA but not AMPA lesioning of the mouse striatum in vivo.	benzamide	19-28	poly (ADP-ribose) polymerase family, member 1	Mus musculus	4-8
14670625-3	2004	Here, we have investigated the time-course of KA-induced toxicity and the effects of the PARP inhibitor benzamide on KA, AMPA and NMDA neurotoxicities in vivo, by measuring changes in the volume of the lesion and in NAD+ and ATP levels induced by the intra-striatal injection of these excitotoxins in C57Bl/6N mice.	benzamide	104-113	poly (ADP-ribose) polymerase family, member 1	Mus musculus	89-93
14751292-3	2004	The present study examined three of these modulators for their effects on synaptic plasticity in field CA1 of hippocampal slices, two of them being the benzamide drugs 1-(quinoxalin-6-ylcarbonyl)piperidine (CX516) and 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine (CX546) which prominently enhance synaptic transmission yet differ in their relative impact on amplitude versus duration of the synaptic response.	benzamide	152-161	carbonic anhydrase 1	Homo sapiens	103-106
12643934-0	2003	Benzamide derivatives as blockers of Kv1.3 ion channel.	benzamide	0-9	potassium voltage-gated channel subfamily A member 3	Homo sapiens	37-42
14969602-2	2003	Studies with a newer benzamide called 123I-epidepride, a high-affinity D2 receptor (D2R) antagonist, showed high sensitivity in D2R-positive pituitary adenomas.	benzamide	21-30	dopamine receptor D2	Homo sapiens	71-82
14969602-2	2003	Studies with a newer benzamide called 123I-epidepride, a high-affinity D2 receptor (D2R) antagonist, showed high sensitivity in D2R-positive pituitary adenomas.	benzamide	21-30	dopamine receptor D2	Homo sapiens	84-87
14969602-2	2003	Studies with a newer benzamide called 123I-epidepride, a high-affinity D2 receptor (D2R) antagonist, showed high sensitivity in D2R-positive pituitary adenomas.	benzamide	21-30	dopamine receptor D2	Homo sapiens	128-131
12617906-0	2003	Cyclic amidines as benzamide bioisosteres: EPC synthesis and SAR studies leading to the selective dopamine D4 receptor agonist FAUC 312.	benzamide	19-28	dopamine receptor D4	Homo sapiens	98-118
12617906-1	2003	Investigation of conformationally restricted benzamide bioisosteres led to the chiral phenyltetrahydropyrimidine derivative ent2a (FAUC 312) displaying strong and highly selective dopamine D4 receptor binding (K(i(high))=1.5 nM).	benzamide	45-54	dopamine receptor D4	Homo sapiens	180-200
12643934-3	2003	A class of benzamide Kv1.3 channel inhibitors has been identified.	benzamide	11-20	potassium voltage-gated channel subfamily A member 3	Homo sapiens	21-26
12459932-0	2003	On the protection against methamphetamine-induced neurotoxicity by benzamide, a PARP inhibitor.	benzamide	67-76	poly(ADP-ribose) polymerase 1	Homo sapiens	80-84
12581860-7	2003	Furthermore, 3-aminobenzamide (3AB) and benzamide, inhibitors of poly (ADP-ribose) polymerase (PARP) that are activated upon recognition of DNA strand breaks, suppressed the further increase by gamma-irradiation in IFN-gamma-induced NO production and the I-kappaB degradation by gamma-irradiation.	benzamide	20-29	poly (ADP-ribose) polymerase family, member 1	Mus musculus	65-93
12581860-7	2003	Furthermore, 3-aminobenzamide (3AB) and benzamide, inhibitors of poly (ADP-ribose) polymerase (PARP) that are activated upon recognition of DNA strand breaks, suppressed the further increase by gamma-irradiation in IFN-gamma-induced NO production and the I-kappaB degradation by gamma-irradiation.	benzamide	20-29	poly (ADP-ribose) polymerase family, member 1	Mus musculus	95-99
12581860-7	2003	Furthermore, 3-aminobenzamide (3AB) and benzamide, inhibitors of poly (ADP-ribose) polymerase (PARP) that are activated upon recognition of DNA strand breaks, suppressed the further increase by gamma-irradiation in IFN-gamma-induced NO production and the I-kappaB degradation by gamma-irradiation.	benzamide	20-29	interferon gamma	Mus musculus	215-224
12165366-1	2002	The aim of the study was to examine the action of low-dose amisulpride (100 mg/d), an atypical antipsychotic from the benzamide class with a high affinity for the D2 and D3 dopamine receptors, given for 4 weeks in 19 schizophrenic patients with the deficit syndrome, in terms of clinical response, modifications in their cognitive performance and changes in brain perfusion values.	benzamide	118-127	dopamine receptor D2	Homo sapiens	163-204
12464646-10	2002	Structure-function analysis indicated that the induction of apoptosis by compounds derived from COX-2 inhibitors required a bulky terminal phenyl ring, a heterocyclic system with negative electrostatic potential, and a benzenesulfonamide or benzenecarboxamide moiety.	benzamide	241-259	prostaglandin-endoperoxide synthase 2	Homo sapiens	96-101
12411406-6	2002	Both 6(5H)-phenanthridinone and benzamide attenuated development of EAE, reducing clinical score, neuroimmune infiltration and expression of inflammatory mediators such as inducible nitric oxide synthase, interleukin-1beta and -2, cyclooxygenase-2, tumour necrosis factor-alpha and interferon-gamma in the spinal cord of myelin-immunized rats.	benzamide	32-41	interleukin 1 beta	Rattus norvegicus	205-229
12411406-6	2002	Both 6(5H)-phenanthridinone and benzamide attenuated development of EAE, reducing clinical score, neuroimmune infiltration and expression of inflammatory mediators such as inducible nitric oxide synthase, interleukin-1beta and -2, cyclooxygenase-2, tumour necrosis factor-alpha and interferon-gamma in the spinal cord of myelin-immunized rats.	benzamide	32-41	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	231-277
12411406-6	2002	Both 6(5H)-phenanthridinone and benzamide attenuated development of EAE, reducing clinical score, neuroimmune infiltration and expression of inflammatory mediators such as inducible nitric oxide synthase, interleukin-1beta and -2, cyclooxygenase-2, tumour necrosis factor-alpha and interferon-gamma in the spinal cord of myelin-immunized rats.	benzamide	32-41	interferon gamma	Rattus norvegicus	282-298
12411406-10	2002	In cultures of activated rat lymphocytes, 6(5H)-phenanthridinone and benzamide reduced the DNA-binding activity of NF-kappaB and AP-1 and transcription of pro-inflammatory cytokines such as interleukin-2, interferon-gamma and tumour necrosis factor-alpha.	benzamide	69-78	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	129-133
12411406-10	2002	In cultures of activated rat lymphocytes, 6(5H)-phenanthridinone and benzamide reduced the DNA-binding activity of NF-kappaB and AP-1 and transcription of pro-inflammatory cytokines such as interleukin-2, interferon-gamma and tumour necrosis factor-alpha.	benzamide	69-78	interleukin 2	Rattus norvegicus	190-203
12411406-10	2002	In cultures of activated rat lymphocytes, 6(5H)-phenanthridinone and benzamide reduced the DNA-binding activity of NF-kappaB and AP-1 and transcription of pro-inflammatory cytokines such as interleukin-2, interferon-gamma and tumour necrosis factor-alpha.	benzamide	69-78	interferon gamma	Rattus norvegicus	205-254
11823129-1	2002	Two benzamide derivatives as dopamine D4 receptor antagonists, YM-50001(4) and N- [2-[4-(4-chlorophenyl]piperizin-1-yl]ethyl]-3-methoxybenzamide (9), were labeled by positron-emitter (11C), and their pharmacological specificities to dopamine D4 receptors were examined by quantitative autoradiography and positron emission tomography (PET).	benzamide	4-13	dopamine receptor D4	Rattus norvegicus	29-49
12207145-0	2002	Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels.	benzamide	37-46	prolactin	Homo sapiens	97-106
11593040-6	2001	Cell death in each condition was markedly reduced by the PARP1 inhibitor benzamide and equally reduced by the PARG inhibitors gallotannin and nobotanin B.	benzamide	73-82	poly (ADP-ribose) polymerase family, member 1	Mus musculus	57-62
11593040-7	2001	The PARP1 inhibitor benzamide and the PARG inhibitor gallotannin both prevented the NAD(+) depletion that otherwise results from PARP1 activation by MNNG or H(2)O(2).	benzamide	20-29	poly (ADP-ribose) polymerase family, member 1	Mus musculus	4-9
11593040-7	2001	The PARP1 inhibitor benzamide and the PARG inhibitor gallotannin both prevented the NAD(+) depletion that otherwise results from PARP1 activation by MNNG or H(2)O(2).	benzamide	20-29	poly (ADP-ribose) polymerase family, member 1	Mus musculus	129-134
11562279-11	2001	The benzamide MS-275 belongs to a new class of synthetic HDAC inhibitors and displays oral activity in animal models.	benzamide	4-13	histone deacetylase 9	Homo sapiens	57-61
15995937-2	2001	Early designs of PARP inhibitors were primarily based on mimicking the structure of nicotinamide and resulted in the identification and widespread use of benzamide analogs as PARP inhibitors.	benzamide	154-163	poly(ADP-ribose) polymerase 1	Homo sapiens	17-21
11549463-0	2001	Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179).	benzamide	0-9	sarcosine dehydrogenase	Homo sapiens	89-92
11549463-0	2001	Benzamide bioisosteres incorporating dihydroheteroazole substructures: EPC synthesis and SAR leading to a selective dopamine D4 receptor partial agonist (FAUC 179).	benzamide	0-9	dopamine receptor D4	Homo sapiens	116-136
11549463-1	2001	Conformationally restricted benzamide bioisosteres were investigated when the chiral phenyldihydroimidazole derivative 4e (FAUC 179) showed strong and highly selective dopamine D4 receptor binding (K(i)high=0.95nM).	benzamide	28-37	dopamine receptor D4	Homo sapiens	168-188
15995937-2	2001	Early designs of PARP inhibitors were primarily based on mimicking the structure of nicotinamide and resulted in the identification and widespread use of benzamide analogs as PARP inhibitors.	benzamide	154-163	poly(ADP-ribose) polymerase 1	Homo sapiens	175-179
10822064-3	2000	In the present study, the antiarrhythmic activity of Benzamide, N-(aminoiminomethyl)-4-?4-(2-furanylcarbonyl)-1-piperazinyl -3-(methy lsulfonyl), methanesulfonate (BIIB 513), a novel NHE-1 inhibitor, was examined.	benzamide	53-62	solute carrier family 9 member A1	Canis lupus familiaris	183-188
11331359-9	2001	Finally, we observed that DTDP toxicity could be blocked with niacinamide or benzamide, inhibitors of poly (ADP-ribose) synthetase.	benzamide	77-86	poly(ADP-ribose) polymerase 1	Homo sapiens	102-130
10869705-6	2000	Coperfusion of SNAP with the free radical scavengers superoxide dismutase (SOD; 60 microg/ml) and catalase (50 microg/ml) reduced or eliminated the ability of the NO-donor to enhance [3H]purine release, but the poly (ADP-ribosyl) synthetase (PARS) inhibitor benzamide (500 microM) did not affect it.	benzamide	258-267	catalase	Homo sapiens	75-106
11049868-4	2000	Intraperitoneal administration of PARP inhibitors, benzamide or 3-amino benzamide, after I/R injury accelerates the recovery of normal renal function, as assessed by monitoring the levels of plasma creatinine and blood urea nitrogen during 6 days postischemia.	benzamide	51-60	poly (ADP-ribose) polymerase 1	Rattus norvegicus	34-38
10841343-5	2000	Gallotannin was more than 10-fold more potent than the PARP inhibitor benzamide in preventing H2O2-induced cell death.	benzamide	70-79	poly (ADP-ribose) polymerase family, member 1	Mus musculus	55-59
10719223-3	2000	Compared to the long form of the D2 receptor (D2(Long)), the short form (D2(Short)) may be three times more sensitive to benzamide antipsychotic drugs.	benzamide	121-130	immunoglobulin heavy diversity 2-15	Homo sapiens	46-54
10704772-7	2000	We now report potent inhibition of p38-MAPK phosphorylation by a synthetic benzamide (CPI-1189) which displays protective action against tumor necrosis factor-alpha (TNFalpha)-induced neurodegeneration.	benzamide	75-84	mitogen-activated protein kinase 14	Homo sapiens	35-38
10704772-7	2000	We now report potent inhibition of p38-MAPK phosphorylation by a synthetic benzamide (CPI-1189) which displays protective action against tumor necrosis factor-alpha (TNFalpha)-induced neurodegeneration.	benzamide	75-84	tumor necrosis factor	Homo sapiens	137-164
10704772-7	2000	We now report potent inhibition of p38-MAPK phosphorylation by a synthetic benzamide (CPI-1189) which displays protective action against tumor necrosis factor-alpha (TNFalpha)-induced neurodegeneration.	benzamide	75-84	tumor necrosis factor	Homo sapiens	166-174
10200742-2	1999	OBJECTIVE: The goal of this placebo-controlled study was to evaluate the efficacy and safety of low doses of amisulpride, an atypical antipsychotic of the benzamide class with high affinity for D2 and D3 dopamine receptors, in the treatment of schizophrenic patients with predominantly primary negative symptoms.	benzamide	155-164	dopamine receptor D2	Homo sapiens	194-222
10649982-1	2000	N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide (1), a high-affinity and selective dopamine D(4) receptor ligand, was chosen as a lead, and structural modifications were done on its amide bond and on its alkyl chain linking the benzamide moiety to the piperazine ring and by preparing some semirigid analogues.	benzamide	55-64	dopamine receptor D4	Homo sapiens	100-122
10647912-4	1999	Ecabapide mainly underwent N-dealkylation to form M1 and 6-hydroxylation of the benzamide moiety to form M6.	benzamide	80-89	cholinergic receptor muscarinic 1	Homo sapiens	50-58
16414805-1	1998	Moclobemide, a benzamide derivative, predominantly inhibits the A form of monoamine oxidase (MAO) and its MAO binding is reversible.	benzamide	15-24	monoamine oxidase A	Rattus norvegicus	74-91
10668429-1	1999	Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide.	benzamide	89-98	poly (ADP-ribose) polymerase family, member 1	Mus musculus	74-78
9453543-7	1998	Several PARP inhibitors [benzamide, 3-aminobenzamide, nicotinamide, and 6(5H)-phenanthridinone] prevented cell death, but the inactive analogue benzoic acid did not.	benzamide	25-34	poly (ADP-ribose) polymerase family, member 1	Mus musculus	8-12
10668429-5	1999	The results confirm that MPTP reduces striatal ATP levels, as previously reported by Chan et al., show that MPTP causes a regionally-selective (striatal and midbrain) loss of NAD+, and indicate that the PARP inhibitor benzamide can prevent these losses without interfering with MPTP-induced striatal dopamine release.	benzamide	218-227	poly (ADP-ribose) polymerase family, member 1	Mus musculus	203-207
9795136-0	1998	Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide.	benzamide	160-169	poly (ADP-ribose) polymerase family, member 1	Mus musculus	121-148
9795136-1	1998	Inhibitors of poly(ADP-ribose) polymerase (PARP), including benzamide, protect against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced dopamine neurotoxicity in vivo [Cosi et al., Brain Res.	benzamide	60-69	poly (ADP-ribose) polymerase family, member 1	Mus musculus	14-41
9795136-1	1998	Inhibitors of poly(ADP-ribose) polymerase (PARP), including benzamide, protect against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced dopamine neurotoxicity in vivo [Cosi et al., Brain Res.	benzamide	60-69	poly (ADP-ribose) polymerase family, member 1	Mus musculus	43-47
9795136-14	1998	]; (2) show that MPTP causes a regionally-dependent (striatal and midbrain) loss of NAD+; (3) indicate that the PARP inhibitor benzamide can prevent these losses without interfering with MPTP-induced striatal dopamine release; and (4) provide further evidence to suggest an involvement of PARP in MPTP-induced neurotoxicity in vivo.	benzamide	127-136	poly (ADP-ribose) polymerase family, member 1	Mus musculus	112-116
9795136-14	1998	]; (2) show that MPTP causes a regionally-dependent (striatal and midbrain) loss of NAD+; (3) indicate that the PARP inhibitor benzamide can prevent these losses without interfering with MPTP-induced striatal dopamine release; and (4) provide further evidence to suggest an involvement of PARP in MPTP-induced neurotoxicity in vivo.	benzamide	127-136	poly (ADP-ribose) polymerase family, member 1	Mus musculus	289-293
16414805-1	1998	Moclobemide, a benzamide derivative, predominantly inhibits the A form of monoamine oxidase (MAO) and its MAO binding is reversible.	benzamide	15-24	monoamine oxidase A	Rattus norvegicus	93-96
16414805-1	1998	Moclobemide, a benzamide derivative, predominantly inhibits the A form of monoamine oxidase (MAO) and its MAO binding is reversible.	benzamide	15-24	monoamine oxidase A	Rattus norvegicus	106-109
9336344-0	1997	An anti-inflammatory benzamide derivative inhibits the protein kinase C (PKC)-dependent pathway of ERK2 phosphorylation in murine macrophages.	benzamide	21-30	mitogen-activated protein kinase 1	Mus musculus	99-103
9336344-1	1997	We have previously described benzamide derivatives that inhibited tumor necrosis factor (TNF) production from activated macrophages (Mphi) probably by interacting with a protein kinase C (PKC)-dependent pathway.	benzamide	29-38	tumor necrosis factor	Mus musculus	66-87
9336344-1	1997	We have previously described benzamide derivatives that inhibited tumor necrosis factor (TNF) production from activated macrophages (Mphi) probably by interacting with a protein kinase C (PKC)-dependent pathway.	benzamide	29-38	tumor necrosis factor	Mus musculus	89-92
9364937-2	1997	Other chemicals, such as benzamide, colchicine, thiamphenicol and paracetamol, that are already known to specifically induce transcription at the hsr omega locus are also identified as amides.	benzamide	25-34	Heat shock RNA omega	Drosophila melanogaster	146-155
9364937-3	1997	In view of the specific induction of the 93D puff by different amides and other data that demonstrate hsr omega transcription in response to benzamide and colchicine etc.	benzamide	141-150	Heat shock RNA omega	Drosophila melanogaster	102-111
10638823-1	1996	The purpose of the present set of studies was to characterize, in vitro and in vivo, two benzamide analogues, 2,3-dimethoxy-N-[1-(4-fluorobenzyl)piperidin4yl]benzamide (MBP) and 4"-fluoroclebopride (FCP), for studying dopamine D2 receptors with Positron Emission Tomography (PET).	benzamide	89-98	myelin basic protein	Macaca mulatta	169-172
9271347-6	1997	Moreover, combined treatment of cells with TZM and benzamide, an inhibitor of the poly(ADP-ribose) polymerase (EC 2.4.2.30), increased the apoptosis induced by the methylating agent.	benzamide	51-60	poly(ADP-ribose) polymerase 1	Homo sapiens	82-109
9166736-10	1997	In contrast, BDP-37, a member of the benzamide family of drugs, exhibited a lower potency for GluR2 flip (58 microM) than for any of the flop isoforms (18-40 microM).	benzamide	37-46	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	94-99
9226586-1	1997	Mosapride citrate, a novel benzamide-type gastroprokinetic agent, is clinically prescribed as a racemate and is metabolized to its des-4-fluorobenzyl structure (M-1).	benzamide	27-36	myoregulin	Homo sapiens	161-164
9212448-0	1997	New benzamide-derived 5-HT3 receptor antagonists which prevent the effects of ethanol on extracellular dopamine, and fail to reduce voluntary alcohol intake in rats.	benzamide	4-13	5-hydroxytryptamine receptor 3A	Rattus norvegicus	22-36
8742516-5	1996	While the PARP-activity remained essentially unchanged, the acetaminophen-induced release of both GOT and GPT from injured liver cells could be inhibited by 90-99%, when mice were injected additionally with the selective PARP-inhibitors nicotinic acid amide, benzamide, caffeine, theophyline, and thymidine, respectively.	benzamide	259-268	glutamic pyruvic transaminase, soluble	Mus musculus	106-109
8911677-0	1996	Benzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouse.	benzamide	0-9	poly (ADP-ribose) polymerase family, member 1	Mus musculus	27-54
8911677-1	1996	Previous studies have indicated that the activation of poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA plasticity-related phenomena, is an early event occurring in glutamate-induced neurotoxicity in vitro, and that inhibitors of PARP, including benzamide, are protective against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro.	benzamide	259-268	poly (ADP-ribose) polymerase family, member 1	Mus musculus	55-82
8911677-1	1996	Previous studies have indicated that the activation of poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA plasticity-related phenomena, is an early event occurring in glutamate-induced neurotoxicity in vitro, and that inhibitors of PARP, including benzamide, are protective against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro.	benzamide	259-268	poly (ADP-ribose) polymerase family, member 1	Mus musculus	84-88
8911677-7	1996	The concentrations of benzamide measured in the striatum at different times following this same dose of drug were in a range (0.09-0.64 mM) reported in in vitro studies to be both neuroprotective and effective in inhibiting PARP activity.	benzamide	22-31	poly (ADP-ribose) polymerase family, member 1	Mus musculus	224-228
8809159-5	1996	Further, the beta 2-AR can accommodate larger substituents such as a benzamide at the 4"-position (26b).	benzamide	69-78	adrenoceptor beta 2	Homo sapiens	13-22
8876997-2	1996	Co-treatments with five different inhibitors of poly(ADP-ribose) polymerase (PARP), including benzamide, significantly prevented the MPTP-induced catecholamine depletions.	benzamide	94-103	poly (ADP-ribose) polymerase family, member 1	Mus musculus	48-75
8876997-2	1996	Co-treatments with five different inhibitors of poly(ADP-ribose) polymerase (PARP), including benzamide, significantly prevented the MPTP-induced catecholamine depletions.	benzamide	94-103	poly (ADP-ribose) polymerase family, member 1	Mus musculus	77-81
8876997-5	1996	The protective activities of benzamide and its derivatives paralleled their in vitro efficacies and potencies both as neuroprotective agents and as inhibitors of PARP, while the activity of 1,5-dihydroxyisoquinoline, a structurally-unrelated compound, did not.	benzamide	29-38	poly (ADP-ribose) polymerase family, member 1	Mus musculus	162-166
8981558-1	1996	Inhibitory effects of the dopamine D2-receptor antagonistic benzamide compound metoclopramide (MCP) on acetylcholinesterase (AChE; EC 3.1.1.7) isoenzymes of both erythrocytes and human caudate nucleus and on human serum cholinesterase (ChE; EC 3.1.1.8) were studied in vitro using a spectrophotometric assay with acetylthiocholine (ASCh) as substrate.	benzamide	60-69	dopamine receptor D2	Homo sapiens	26-46
8981558-1	1996	Inhibitory effects of the dopamine D2-receptor antagonistic benzamide compound metoclopramide (MCP) on acetylcholinesterase (AChE; EC 3.1.1.7) isoenzymes of both erythrocytes and human caudate nucleus and on human serum cholinesterase (ChE; EC 3.1.1.8) were studied in vitro using a spectrophotometric assay with acetylthiocholine (ASCh) as substrate.	benzamide	60-69	acetylcholinesterase (Cartwright blood group)	Homo sapiens	103-123
8981558-1	1996	Inhibitory effects of the dopamine D2-receptor antagonistic benzamide compound metoclopramide (MCP) on acetylcholinesterase (AChE; EC 3.1.1.7) isoenzymes of both erythrocytes and human caudate nucleus and on human serum cholinesterase (ChE; EC 3.1.1.8) were studied in vitro using a spectrophotometric assay with acetylthiocholine (ASCh) as substrate.	benzamide	60-69	acetylcholinesterase (Cartwright blood group)	Homo sapiens	125-129
8981558-1	1996	Inhibitory effects of the dopamine D2-receptor antagonistic benzamide compound metoclopramide (MCP) on acetylcholinesterase (AChE; EC 3.1.1.7) isoenzymes of both erythrocytes and human caudate nucleus and on human serum cholinesterase (ChE; EC 3.1.1.8) were studied in vitro using a spectrophotometric assay with acetylthiocholine (ASCh) as substrate.	benzamide	60-69	butyrylcholinesterase	Homo sapiens	109-123
8981558-1	1996	Inhibitory effects of the dopamine D2-receptor antagonistic benzamide compound metoclopramide (MCP) on acetylcholinesterase (AChE; EC 3.1.1.7) isoenzymes of both erythrocytes and human caudate nucleus and on human serum cholinesterase (ChE; EC 3.1.1.8) were studied in vitro using a spectrophotometric assay with acetylthiocholine (ASCh) as substrate.	benzamide	60-69	butyrylcholinesterase	Homo sapiens	126-129
9081862-1	1996	The 93D, or hsr-omega (heat-shock RNA-omega), locus of Drosophila melanogaster and other species of Drosophila, besides being induced as a member of the heat shock gene family, is also selectively and singularly inducible by a variety of agents, notably benzamide, colchicine and vitamin B6 (in species other than D. melanogaster).	benzamide	254-263	Heat shock RNA omega	Drosophila melanogaster	12-21
8569793-0	1996	Reversion in Chinese hamster lines amplified at the AMPD2 locus: spontaneous and benzamide-stimulated gradual loss of amplified alleles of marker genes.	benzamide	81-90	AMP deaminase 2	Cricetulus griseus	52-57
8742516-5	1996	While the PARP-activity remained essentially unchanged, the acetaminophen-induced release of both GOT and GPT from injured liver cells could be inhibited by 90-99%, when mice were injected additionally with the selective PARP-inhibitors nicotinic acid amide, benzamide, caffeine, theophyline, and thymidine, respectively.	benzamide	259-268	poly (ADP-ribose) polymerase family, member 1	Mus musculus	221-225
7562546-6	1995	More likely, these benzamide derivatives acted mainly at the level of the protein kinase C (PKC) pathway because: 1) After treatment of M phi with PKC inhibitors which significantly inhibited TNF production, our compounds showed no additional inhibition.	benzamide	19-28	tumor necrosis factor	Homo sapiens	192-195
8135490-8	1993	It has structural resemblance to some of the known inhibitors of the DNA associated enzyme poly ADPRT such as benzamide.	benzamide	110-119	ADP-ribosyltransferase 1	Mus musculus	96-101
7562546-4	1995	We show that, in marked contrast with ibuprofen, flurbiprofen and indomethacin which all significantly enhanced TNF production, the two benzamide derivatives tested, JM34 and JM42, significantly inhibited TNF-alpha production by zymosan or lipopolysaccharide-activated M phi.	benzamide	136-145	tumor necrosis factor	Homo sapiens	205-214
8038764-0	1994	Synthesis of 11C-labelled benzamide compounds as potential tracers for poly(ADP-ribose) synthetase.	benzamide	26-35	poly(ADP-ribose) polymerase 1	Homo sapiens	71-98
8145235-3	1994	Replacement of the benzamide portion of the (p-aminobenzoyl)glutamate moiety with 2-fluorobenzamido, 2-isoindolinyl, 1,2-benzisothiazol-2-yl, and 2-thenamido moieties varied in effect from a 9-fold diminution of TS activity to a 5-fold enhancement, while cytotoxic potency on SW-480 and MCF-7 tumor lines showed increases ranging from 3.6- to 450-fold.	benzamide	19-28	thymidylate synthetase	Homo sapiens	212-214
7553982-4	1995	Among them, some benzamide derivatives having a 1,4-diazepine ring showed a potent 5-HT3 receptor antagonistic activity.	benzamide	17-26	5-hydroxytryptamine receptor 3A	Rattus norvegicus	83-97
7540096-2	1995	While heat shock increased the levels of all the three transcripts at the 93D puff site in a coordinated manner, benzamide led to a significant increase in the levels of hsr-omega-n and pre-c; on the other hand, colchicine caused increased levels of the omega-n and omega-c RNA species at 93D.	benzamide	113-122	Heat shock RNA omega	Drosophila melanogaster	170-181
7540096-5	1995	Although a combined treatment to salivary glands with heat shock and benzamide or colchicine is known to inhibit puffing and [3H]uridine incorporation at 93D, the two treatments resulted in a treatment-specific increase in the in situ levels of different hsr-omega transcripts at the 93D site, suggesting a reduced turnover of specific transcripts from the site under these conditions.	benzamide	69-78	Heat shock RNA omega	Drosophila melanogaster	255-264
8306827-5	1993	The association of HSP90 with the 93D locus was strictly heat shock dependent as shown by the absence of HSP90 in puff 93D induced by either benzamide or colchicine.	benzamide	141-150	Heat shock protein 83	Drosophila melanogaster	19-24
7690896-3	1993	A similar important role of BrdUrd in SCE induction has been reported in the cases of benzamide (BA) (Natarajan et al., 1981) and camptothecin (CPT) (Zhao et al., 1992), which are inhibitors of poly(ADP-ribose)polymerase and DNA topoisomerase I (topo I), respectively.	benzamide	86-95	poly(ADP-ribose) polymerase 1	Homo sapiens	194-220
7690896-3	1993	A similar important role of BrdUrd in SCE induction has been reported in the cases of benzamide (BA) (Natarajan et al., 1981) and camptothecin (CPT) (Zhao et al., 1992), which are inhibitors of poly(ADP-ribose)polymerase and DNA topoisomerase I (topo I), respectively.	benzamide	97-99	poly(ADP-ribose) polymerase 1	Homo sapiens	194-220
8255982-2	1993	Moclobemide is a novel benzamide reversible inhibitor of monoamine oxidase A and has clinical efficacy in a wide spectrum of depressive illness including endogenous and non-endogenous depression, in younger adults and in the elderly.	benzamide	23-32	monoamine oxidase A	Homo sapiens	57-76
8241609-2	1993	Tiapride is a substituted benzamide derivative with selective dopamine D2-receptor antagonist properties which appears to have preferential affinity for extrastriatal dopamine receptors.	benzamide	26-35	dopamine receptor D2	Homo sapiens	62-82
8347172-5	1993	ABA and BA inhibited the activity of poly(ADP-ribose) polymerase by 85%.	benzamide	1-3	poly (ADP-ribose) polymerase family, member 1	Mus musculus	37-64
8347172-12	1993	With the cultured hepatocytes, ABA and BA inhibited poly(ADP-ribose) polymerase at concentrations that were without effect on either the extent of cell killing or the depletion of NAD occurring with either TBHP, H2O2, or menadione.	benzamide	32-34	poly (ADP-ribose) polymerase family, member 1	Mus musculus	52-79
8232288-0	1993	Characterization of the superinduction of the c-myc proto-oncogene in fibroblasts by benzamide derivatives.	benzamide	85-94	myelocytomatosis oncogene	Mus musculus	46-66
1535660-0	1992	Conformational analysis of dopamine D-2 receptor antagonists of the benzamide series in relation to a recently proposed D-2 receptor-interaction model.	benzamide	68-77	dopamine receptor D2	Homo sapiens	27-48
7682390-2	1993	Both this ADP-ribosylation reaction and granulocytic differentiation in response to recombinant G-CSF were inhibited approximately 50% by 2 mM benzamide, suggesting a correlation between these two processes.	benzamide	143-152	peripheral blood stem cell response to granulocyte colony stimulating factor 1	Mus musculus	96-101
1327852-5	1992	A range of competitive inhibitors (benzamide and its derivatives) of the nuclear enzyme poly(ADP-ribose) polymerase (PADPRP; EC 2.4.2.30) was utilized, and their ability to induce melanogenesis reflected their potency as PADPRP inhibitors.	benzamide	35-44	poly (ADP-ribose) polymerase family, member 1	Mus musculus	88-115
1327852-5	1992	A range of competitive inhibitors (benzamide and its derivatives) of the nuclear enzyme poly(ADP-ribose) polymerase (PADPRP; EC 2.4.2.30) was utilized, and their ability to induce melanogenesis reflected their potency as PADPRP inhibitors.	benzamide	35-44	poly (ADP-ribose) polymerase family, member 1	Mus musculus	117-123
1327852-5	1992	A range of competitive inhibitors (benzamide and its derivatives) of the nuclear enzyme poly(ADP-ribose) polymerase (PADPRP; EC 2.4.2.30) was utilized, and their ability to induce melanogenesis reflected their potency as PADPRP inhibitors.	benzamide	35-44	poly (ADP-ribose) polymerase family, member 1	Mus musculus	221-227
1394694-0	1992	Synthesis and evaluation of iodinated benzamide derivatives as selective and reversible monoamine oxidase B inhibitors.	benzamide	38-47	monoamine oxidase B	Homo sapiens	88-107
1617671-6	1992	The inhibitors of ADP-ribose transferase benzamide and 3-amino-benzamide suppressed the elongation of the c-fos message and the de novo synthesis of nuclear factors, among them c-Fos and c-Jun, which bind to the fos-AP-1 motif in vitro only following stimulation with active oxygen.	benzamide	41-50	FBJ osteosarcoma oncogene	Mus musculus	106-111
1617671-6	1992	The inhibitors of ADP-ribose transferase benzamide and 3-amino-benzamide suppressed the elongation of the c-fos message and the de novo synthesis of nuclear factors, among them c-Fos and c-Jun, which bind to the fos-AP-1 motif in vitro only following stimulation with active oxygen.	benzamide	41-50	FBJ osteosarcoma oncogene	Mus musculus	177-182
1617671-6	1992	The inhibitors of ADP-ribose transferase benzamide and 3-amino-benzamide suppressed the elongation of the c-fos message and the de novo synthesis of nuclear factors, among them c-Fos and c-Jun, which bind to the fos-AP-1 motif in vitro only following stimulation with active oxygen.	benzamide	41-50	jun proto-oncogene	Mus musculus	187-192
1617671-6	1992	The inhibitors of ADP-ribose transferase benzamide and 3-amino-benzamide suppressed the elongation of the c-fos message and the de novo synthesis of nuclear factors, among them c-Fos and c-Jun, which bind to the fos-AP-1 motif in vitro only following stimulation with active oxygen.	benzamide	41-50	FBJ osteosarcoma oncogene	Mus musculus	108-111
1773788-1	1991	A poly(ADP-ribose) polymerase inhibitor, benzamide (BA), was found to induce flat revertants of NIH 3T3 cells that had been transformed by human Ha-ras, rat Ki-ras, rat c-raf, and human ret-II.	benzamide	41-50	poly(ADP-ribose) polymerase 1	Homo sapiens	2-29
1660277-3	1991	The amplified catalase and c-myc genes in HP100-1 cells were not decreased by treatment of the cells with inhibitors of poly(ADP-Ribose) polymerase, such as nicotinamide and benzamide.	benzamide	174-183	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	27-32
1773788-1	1991	A poly(ADP-ribose) polymerase inhibitor, benzamide (BA), was found to induce flat revertants of NIH 3T3 cells that had been transformed by human Ha-ras, rat Ki-ras, rat c-raf, and human ret-II.	benzamide	41-50	KRAS proto-oncogene, GTPase	Rattus norvegicus	157-163
1773788-1	1991	A poly(ADP-ribose) polymerase inhibitor, benzamide (BA), was found to induce flat revertants of NIH 3T3 cells that had been transformed by human Ha-ras, rat Ki-ras, rat c-raf, and human ret-II.	benzamide	41-50	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	169-174
1773788-1	1991	A poly(ADP-ribose) polymerase inhibitor, benzamide (BA), was found to induce flat revertants of NIH 3T3 cells that had been transformed by human Ha-ras, rat Ki-ras, rat c-raf, and human ret-II.	benzamide	41-50	golgin A5	Homo sapiens	186-192
1773788-1	1991	A poly(ADP-ribose) polymerase inhibitor, benzamide (BA), was found to induce flat revertants of NIH 3T3 cells that had been transformed by human Ha-ras, rat Ki-ras, rat c-raf, and human ret-II.	benzamide	52-54	poly(ADP-ribose) polymerase 1	Homo sapiens	2-29
1773788-1	1991	A poly(ADP-ribose) polymerase inhibitor, benzamide (BA), was found to induce flat revertants of NIH 3T3 cells that had been transformed by human Ha-ras, rat Ki-ras, rat c-raf, and human ret-II.	benzamide	52-54	KRAS proto-oncogene, GTPase	Rattus norvegicus	157-163
1773788-1	1991	A poly(ADP-ribose) polymerase inhibitor, benzamide (BA), was found to induce flat revertants of NIH 3T3 cells that had been transformed by human Ha-ras, rat Ki-ras, rat c-raf, and human ret-II.	benzamide	52-54	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	169-174
1773788-1	1991	A poly(ADP-ribose) polymerase inhibitor, benzamide (BA), was found to induce flat revertants of NIH 3T3 cells that had been transformed by human Ha-ras, rat Ki-ras, rat c-raf, and human ret-II.	benzamide	52-54	golgin A5	Homo sapiens	186-192
1901170-3	1991	Two inhibitors of ADPRT, benzamide, competing with NAD at the nicotinamide binding site, and 6-amino-1,2-benzopyrone, which competes with DNA at the DNA binding site(s), both selectively arrest differentiation at the prodissoconch stage.	benzamide	25-34	poly [ADP-ribose] polymerase 1	Bos taurus	18-23
2139420-9	1990	Inhibitors of ADPRT, nicotinamide, caffeine and benzamide inhibited the induction of ODC by PHA in a concentration-dependent manner, in the range (0.6-10 mM) known to inhibit ADPRT.	benzamide	48-57	ornithine decarboxylase 1	Homo sapiens	85-88
2144583-9	1990	It is concluded that the D2 dopamine receptor binding site contains separate but over-lapping binding regions for antagonists such as spiperone and substituted benzamide drugs.	benzamide	160-169	dopamine receptor D2	Homo sapiens	25-45
2123732-5	1990	Following treatment of these cells with 2 mM benzamide, an inhibitor of the NAD(+)-utilizing enzyme poly(ADP-ribose) polymerase, NAD+ levels slowly increased up to about 160% of control levels after 3 hours.	benzamide	45-54	poly (ADP-ribose) polymerase family, member 1	Mus musculus	100-127
2139420-9	1990	Inhibitors of ADPRT, nicotinamide, caffeine and benzamide inhibited the induction of ODC by PHA in a concentration-dependent manner, in the range (0.6-10 mM) known to inhibit ADPRT.	benzamide	48-57	poly(ADP-ribose) polymerase 1	Homo sapiens	175-180
34885822-3	2021	In this study, a series of novel CRBN-recruiting HDAC PROTACs were designed and synthesized by linking hydroxamic acid and benzamide with lenalidomide, pomalidomide, and CC-220 through linkers of different lengths and types.	benzamide	123-132	cereblon	Homo sapiens	33-37
2143753-0	1990	Preparation and biological evaluation of 18F-labeled benzamide analogs as potential dopamine D2 receptor ligands.	benzamide	53-62	dopamine receptor D2	Homo sapiens	84-104
2143753-1	1990	Three 18F-labeled benzamide derivatives were prepared and evaluated as potential ligands to study the dopamine D2 receptor phenomenon.	benzamide	18-27	dopamine receptor D2	Homo sapiens	102-122
34894610-8	2022	Among the tested compounds 7a with benzamide moiety was the most potent dual DOR/KOR agonist.	benzamide	35-44	opioid receptor kappa 1	Homo sapiens	81-84
34729902-0	2021	Mechanistic insights into the selective dual BET and PLK1 inhibitory activity of a novel benzamide compound in castration-resistant prostate cancer.	benzamide	89-98	delta/notch like EGF repeat containing	Homo sapiens	45-48
34729902-0	2021	Mechanistic insights into the selective dual BET and PLK1 inhibitory activity of a novel benzamide compound in castration-resistant prostate cancer.	benzamide	89-98	polo like kinase 1	Homo sapiens	53-57
34885822-3	2021	In this study, a series of novel CRBN-recruiting HDAC PROTACs were designed and synthesized by linking hydroxamic acid and benzamide with lenalidomide, pomalidomide, and CC-220 through linkers of different lengths and types.	benzamide	123-132	histone deacetylase 9	Homo sapiens	49-53
34478925-6	2021	Accordingly, in this paper, we have developed a reliable virtual screening process, combining different ligand- and structure-based methods, to identify novel benzamide-based analogs with potential HDAC1 inhibitory activity.	benzamide	159-168	histone deacetylase 1	Homo sapiens	198-203
34478925-7	2021	For this purpose, a focused library of 736,160 compounds from PubChem database was first compiled based on 80% structural similarity with four known benzamide-based HDAC1 inhibitors, Mocetinostat, Entinostat, Tacedinaline, and Chidamide.	benzamide	149-158	histone deacetylase 1	Homo sapiens	165-170
34428714-2	2021	Delightfully, benzylamine derivatives (14-27) exhibited higher ATX inhibitory potency with IC50 value ranging from 1.72 to 497 nM superior to benzamide analogues (8-13).	benzamide	142-151	ectonucleotide pyrophosphatase/phosphodiesterase 2	Homo sapiens	63-66
34478925-13	2021	In summary, the presented computational approach can provide a set of guidelines for the further development of improved benzamide-based derivatives targeting HDAC1 isoform.	benzamide	121-130	histone deacetylase 1	Homo sapiens	159-164
34314075-0	2021	Cf-02, a novel benzamide-linked small molecule, blunts NF-kappaB activation and NLRP3 inflammasome assembly and improves acute onset of accelerated and severe lupus nephritis in mice.	benzamide	15-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	55-64
34120025-0	2021	Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.	benzamide	86-95	histone deacetylase 3	Mus musculus	123-128
34314075-0	2021	Cf-02, a novel benzamide-linked small molecule, blunts NF-kappaB activation and NLRP3 inflammasome assembly and improves acute onset of accelerated and severe lupus nephritis in mice.	benzamide	15-24	NLR family, pyrin domain containing 3	Mus musculus	80-85
34314075-1	2021	In the present study, acute onset of severe lupus nephritis was successfully treated in mice using a new, benzamide-linked, small molecule that targets immune modulation and the NLRP3 inflammasome.	benzamide	106-115	NLR family, pyrin domain containing 3	Mus musculus	178-183
35325883-3	2022	To gain specific targeting properties, NCs, XT5 molecules (a benzamide derivative) which shows high affinity properties against protease-activated receptor-1 (PAR1), that overexpressed in myeloma cancer cells, was used.	benzamide	61-70	coagulation factor II thrombin receptor	Homo sapiens	128-157
34165688-0	2022	New benzamide derivatives and their nicotinamide/cinnamamide analogs as cholinesterase inhibitors.	benzamide	4-13	butyrylcholinesterase	Homo sapiens	72-86
34165688-1	2022	In this study, a total of 18 new benzamide/ nicotinamide/ cinnamamide derivative compounds were designed and synthesized for the first time (except B1 and B5) by conventional and microwave irradiation methods.	benzamide	33-42	immunoglobulin kappa variable 7-3 (pseudogene)	Homo sapiens	148-157
35598794-0	2022	Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors.	benzamide	53-62	epoxide hydrolase 2	Homo sapiens	101-104
35483594-0	2022	In silico, synthesis and anticancer evaluation of benzamide tryptamine derivatives as novel eEF2K inhibitors.	benzamide	50-59	eukaryotic elongation factor 2 kinase	Homo sapiens	92-97
35325883-3	2022	To gain specific targeting properties, NCs, XT5 molecules (a benzamide derivative) which shows high affinity properties against protease-activated receptor-1 (PAR1), that overexpressed in myeloma cancer cells, was used.	benzamide	61-70	coagulation factor II thrombin receptor	Homo sapiens	159-163
35337122-0	2022	Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer (18F)BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain.	benzamide	78-87	histone deacetylase 1	Homo sapiens	130-158
35450381-0	2022	Design, Synthesis, and Evaluation of PD-1/PD-L1 Antagonists Bearing a Benzamide Scaffold.	benzamide	70-79	CD274 molecule	Sus scrofa	42-47
35450381-3	2022	In this work, a series of novel benzamide derivatives were designed, synthesized, and evaluated to find effective inhibitors of the PD-1/PD-L1 interaction.	benzamide	32-41	CD274 molecule	Sus scrofa	137-142
35337122-3	2022	The aim of this work is the development of a novel 18F-labelled HDAC1/2-specific inhibitor with a benzamide-based zinc-binding group to visualize these enzymes in brain tumours by positron emission tomography (PET).	benzamide	98-107	histone deacetylase 1	Homo sapiens	64-71
2529540-2	1989	On differentiation of the HL-60 cells into granulocytes induced by several inhibitors of poly(ADP-ribose) polymerase [NAD+ poly(adenosine diphosphate D-ribose)ADP-D-ribosyltransferase, EC 2.4.2.30] including benzamide, nicotinamide, coumarin, and 4-hydroxyquinazoline or dimethyl sulfoxide, some MYC loss was observed.	benzamide	208-217	poly(ADP-ribose) polymerase 1	Homo sapiens	89-116
2531826-0	1989	[125]I-spectramide: a novel benzamide displaying potent and selective effects at the D2 dopamine receptor.	benzamide	28-37	dopamine receptor D2	Rattus norvegicus	85-105
2555720-0	1989	The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons.	benzamide	32-41	5 hydroxytryptamine (serotonin) receptor 4	Mus musculus	103-108
2507758-3	1989	Benzamide (Bz), an inhibitor of adenosine diphosphoribosyl transferase (ADPRT), does not modify the lethal effect of UVC radiation in L5178Y-R cells, whereas it sensitizes L5178Y-S cells.	benzamide	0-9	ADP-ribosyltransferase 1	Mus musculus	32-70
2507758-3	1989	Benzamide (Bz), an inhibitor of adenosine diphosphoribosyl transferase (ADPRT), does not modify the lethal effect of UVC radiation in L5178Y-R cells, whereas it sensitizes L5178Y-S cells.	benzamide	0-9	ADP-ribosyltransferase 1	Mus musculus	72-77
2507758-3	1989	Benzamide (Bz), an inhibitor of adenosine diphosphoribosyl transferase (ADPRT), does not modify the lethal effect of UVC radiation in L5178Y-R cells, whereas it sensitizes L5178Y-S cells.	benzamide	11-13	ADP-ribosyltransferase 1	Mus musculus	32-70
2507758-3	1989	Benzamide (Bz), an inhibitor of adenosine diphosphoribosyl transferase (ADPRT), does not modify the lethal effect of UVC radiation in L5178Y-R cells, whereas it sensitizes L5178Y-S cells.	benzamide	11-13	ADP-ribosyltransferase 1	Mus musculus	72-77
2977324-1	1988	IBZM is one of several benzamide derivatives showing a high affinity for the CNS D-2 dopamine receptor.	benzamide	23-32	dopamine receptor D2	Homo sapiens	81-102
2500442-11	1989	Drugs (such as benzamide and colchicine) that induce puffing of hsr omega, but not other heat shock loci, lead to large increases in omega 1.	benzamide	15-24	Heat shock RNA omega	Drosophila melanogaster	64-73
3148319-1	1988	The effect of treatment with benzamide, an inhibitor of adenosine diphosphate (ADP) ribosyl polymerase (ADPRP) was studied in cells of two strains of L5178Y (LY) murine lymphoma exposed to ionizing radiation.	benzamide	29-38	poly (ADP-ribose) polymerase family, member 1	Mus musculus	104-109
3124848-1	1987	Structural analogues of benzamide (BA) containing a sulfur atom were tested for their ability to inhibit the enzyme poly(ADP-ribose)transferase (ADPRT) in cultured Chinese Hamster Ovary (CHO) cells.	benzamide	24-33	poly [ADP-ribose] polymerase 1	Cricetulus griseus	116-143
3124848-1	1987	Structural analogues of benzamide (BA) containing a sulfur atom were tested for their ability to inhibit the enzyme poly(ADP-ribose)transferase (ADPRT) in cultured Chinese Hamster Ovary (CHO) cells.	benzamide	24-33	poly [ADP-ribose] polymerase 1	Cricetulus griseus	145-150
3124848-1	1987	Structural analogues of benzamide (BA) containing a sulfur atom were tested for their ability to inhibit the enzyme poly(ADP-ribose)transferase (ADPRT) in cultured Chinese Hamster Ovary (CHO) cells.	benzamide	35-37	poly [ADP-ribose] polymerase 1	Cricetulus griseus	116-143
3124848-1	1987	Structural analogues of benzamide (BA) containing a sulfur atom were tested for their ability to inhibit the enzyme poly(ADP-ribose)transferase (ADPRT) in cultured Chinese Hamster Ovary (CHO) cells.	benzamide	35-37	poly [ADP-ribose] polymerase 1	Cricetulus griseus	145-150
3124848-5	1987	TCA, an isostere of BA, produced some inhibition of ADPRT, although its activity was markedly lower than that of the parental drug.	benzamide	20-22	poly [ADP-ribose] polymerase 1	Cricetulus griseus	52-57
3742029-4	1986	Other benzamide derivatives were less active in inhibiting MAO-A and had but a negligible effect on dopamine- and 2-phenylethylamine deamination.	benzamide	6-15	monoamine oxidase A	Rattus norvegicus	59-64
2942307-1	1986	The effect of nicotinamide or benzamide, inhibitors of poly(ADP-ribose)polymerase activity, on X-ray and ultraviolet light induced killing of asynchronously dividing V79 Chinese hamster cells was to reduce the shoulder width of the survival curve; the rate of killing remaining unchanged and the yield of 8-azaguanine resistant mutants also remaining unaffected.	benzamide	30-39	poly [ADP-ribose] polymerase 1	Cricetulus griseus	55-81
3132517-5	1987	The radiometric test procedure (CV 20-25%) is critically validated and kinetic properties of serum ADPRT have been studied, showing a competitive inhibition by nicotinamide, benzamide and 3-aminobenzamide.	benzamide	174-183	poly(ADP-ribose) polymerase 1	Homo sapiens	99-104
3299396-2	1987	The substituted benzamide, sulpiride, a selective dopamine D-2 receptor antagonist, significantly increased the consumption of water and hypotonic saline at 30 mg/kg.	benzamide	16-25	solute carrier family 3 member 1	Rattus norvegicus	59-62
3114030-1	1987	Previous studies have shown that benzamide and nicotinamide, two inhibitors of poly(ADP-ribose) polymerase, induce erythroid differentiation in Friend erythroleukemic cells.	benzamide	33-42	poly(ADP-ribose) polymerase 1	Homo sapiens	79-106
4030988-3	1985	Internal standards were a new substituted benzamide (N-[(ethyl-1-pyrrolidinyl-2)methyl] methoxy-2-ethylsulphonyl-5-benzamide, DAN) for the sulpiride assay and sulpiride for the sultopride assay.	benzamide	42-51	NBL1, DAN family BMP antagonist	Homo sapiens	126-129
3088638-1	1986	BRL 20596 (N-(4-amino-5-chloro-2-methoxyphenyl)-1-phenylmethyl-4-piperidine-carbox amide) is a novel anilide related to clebopride (a gastric prokinetic benzamide) in which the sole change is reversal of the amide bond.	benzamide	153-162	bromodomain containing 1	Homo sapiens	0-3
3761757-5	1986	In the D-2 receptor assay, the IC50 values of tiapride and sulpiride were 1/22.7 and 1/19.1 of those in the presence of 100 mM NaCl, respectively, suggesting that benzamide drug binds to the D-2 subtype with higher affinity in the presence of Na+ than in the control.	benzamide	163-172	solute carrier family 3 member 1	Rattus norvegicus	7-10
3761757-5	1986	In the D-2 receptor assay, the IC50 values of tiapride and sulpiride were 1/22.7 and 1/19.1 of those in the presence of 100 mM NaCl, respectively, suggesting that benzamide drug binds to the D-2 subtype with higher affinity in the presence of Na+ than in the control.	benzamide	163-172	solute carrier family 3 member 1	Rattus norvegicus	191-194
6616329-1	1983	While a first injection of the antidopaminergic benzamide drug, sulpiride, induced a large rise in plasma prolactin (PRL) levels in chronically cannulated adult male rats, a second injection given 2 h later was totally inactive although the pituitary content of the hormone was still 76% of the initial value.	benzamide	48-57	prolactin	Rattus norvegicus	106-115
6196785-4	1983	Benzamide (10 microM intracellular concentration), a specific inhibitor of poly(ADP-ribose) polymerase, prevented transformation in a cell cycle-specific manner, maximal prevention coinciding with early S phase, also characteristic of maximal susceptibility to transformation.	benzamide	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	75-102
4026902-4	1985	The reversible and specific monoamine oxidase (MAO)-A inhibitor moclobemide, a benzamide, is therefore completely different from the classical irreversible MAO inhibitors of the hydrazine type and, as also confirmed in the clinical studies, does not have any hepatotoxic effect.	benzamide	79-88	monoamine oxidase A	Rattus norvegicus	28-53
4026902-4	1985	The reversible and specific monoamine oxidase (MAO)-A inhibitor moclobemide, a benzamide, is therefore completely different from the classical irreversible MAO inhibitors of the hydrazine type and, as also confirmed in the clinical studies, does not have any hepatotoxic effect.	benzamide	79-88	monoamine oxidase A	Rattus norvegicus	47-50
6388247-2	1984	Moclobemide (Ro 11-1163), a benzamide derivative, is a MAO-inhibitor which selectively and reversibly inhibits monoamine oxidase type A.	benzamide	28-37	monoamine oxidase A	Homo sapiens	111-135
6087814-1	1984	Rats fed a synthetic diet containing 0.25% benzamide, 0.1% phenobarbital, separately or in combination, for two weeks showed a significant augmentation in the activity of nuclear poly(ADP-ribose) polymerase as well as changes in various nuclear, microsomal and cytosolic liver enzymes involved in the metabolism of xenobiotics.	benzamide	43-52	poly (ADP-ribose) polymerase 1	Rattus norvegicus	179-206
6616329-1	1983	While a first injection of the antidopaminergic benzamide drug, sulpiride, induced a large rise in plasma prolactin (PRL) levels in chronically cannulated adult male rats, a second injection given 2 h later was totally inactive although the pituitary content of the hormone was still 76% of the initial value.	benzamide	48-57	prolactin	Rattus norvegicus	117-120
1147723-2	1975	Four structuraly related benzamide derivative (1211, 1265, 1308 and 1347) also stimutated the ileum, 1211 being the most active, and 1347  the least active, and resembled Mcp  with regard to the responses to Ac, transmural stimulation and histamine.	benzamide	25-34	membrane cofactor protein	Cavia porcellus	171-174
6855475-2	1983	Nevertheless, the IC50 values for the inhibition of 3H-spiperone binding by the seven substituted benzamide drugs was significantly correlated with their high potency to stimulate rat PRL secretion in vivo.	benzamide	98-107	prolactin	Rattus norvegicus	184-187
6855475-5	1983	This data suggests that blockade of different subgroups of dopamine receptors in the anterior pituitary gland labeled by 3H-spiperone may be responsible for the in vivo stimulation of PRL secretion by the benzamide and non-benzamide neuroleptic drugs.	benzamide	205-214	prolactin	Rattus norvegicus	184-187
7256107-1	1981	The authors report results attained by means of a replaced benzamide, thiapride, in the treatment of 21 subjects showing involuntary movements of extra-pyramidal origin and more exactly: extra-pyramidal syndromes due to drugs (3), idiopathic dyscinesias (8), choreas (6), dystonias (3), essential tremor (1).	benzamide	59-68	dopamine receptor D3	Homo sapiens	287-307
6884428-2	1983	The inhibition by (-)-NCA was reversible and antagonized by the benzamide neuroleptic S-sulpiride.	benzamide	64-73	CEA cell adhesion molecule 6	Homo sapiens	22-25
6827920-0	1983	Effect of a novel benzamide, YM-09151-2, on rat serum prolactin levels.	benzamide	18-27	prolactin	Rattus norvegicus	54-63
6827920-4	1983	This benzamide was also a potent blocker of DA-induced inhibition of prolactin release in vitro and was very effective in displacing 3H-spiperone from bovine pituitary membranes: IC50, 1.04nM.	benzamide	5-14	prolactin	Bos taurus	69-78
6307677-1	1983	Benzamide and 3-aminobenzamide, inhibitors of poly(ADP-ribose) polymerase, synergistically enhanced the frequencies of unscheduled DNA synthesis and sister chromatid exchanges in Chinese hamster ovary (CHO) cells treated with N-methyl-N"-nitro-N-nitrosoguanidine (MNNG).	benzamide	0-9	poly [ADP-ribose] polymerase 1	Cricetulus griseus	46-73
33987736-0	2021	Identification of benzamide inhibitors of histone deacetylase 1 from Babesia and Theileria species via high-throughput virtual screening and molecular dynamics simulations.	benzamide	18-27	histone deacetylase 1	Homo sapiens	42-63
33987736-6	2021	We have herein focused on the class I HDAC enzyme, HDAC1, of the Babesia and Theileria species to discover potential benzamide inhibitors by following a streamlined workflow of computer-aided drug design methodology.	benzamide	117-126	histone deacetylase 9	Homo sapiens	38-42
33577290-0	2021	PT3: A Novel Benzamide Class Histone Deacetylase 3 Inhibitor Improves Learning and Memory in Novel Object Recognition Mouse Model.	benzamide	13-22	histone deacetylase 3	Mus musculus	29-50
33858315-0	2022	Evaluation of Benzamide-chalcone Derivatives as EGFR/CDK2 inhibitor: Synthesis, in-vitro Inhibition, and Molecular Modeling Studies.	benzamide	14-23	epidermal growth factor receptor	Homo sapiens	48-52
33858315-0	2022	Evaluation of Benzamide-chalcone Derivatives as EGFR/CDK2 inhibitor: Synthesis, in-vitro Inhibition, and Molecular Modeling Studies.	benzamide	14-23	cyclin dependent kinase 2	Homo sapiens	53-57
33858315-17	2022	CONCLUSION: These benzamide-substituted chalcone derivatives will be useful as lead molecules for the further development of newer inhibitors of EGFR and/or CDK2 kinases.	benzamide	18-27	epidermal growth factor receptor	Homo sapiens	145-149
33858315-17	2022	CONCLUSION: These benzamide-substituted chalcone derivatives will be useful as lead molecules for the further development of newer inhibitors of EGFR and/or CDK2 kinases.	benzamide	18-27	cyclin dependent kinase 2	Homo sapiens	157-161
33987736-6	2021	We have herein focused on the class I HDAC enzyme, HDAC1, of the Babesia and Theileria species to discover potential benzamide inhibitors by following a streamlined workflow of computer-aided drug design methodology.	benzamide	117-126	histone deacetylase 1	Homo sapiens	51-56
33987736-7	2021	Molecular docking and molecular dynamics simulations revealed that benzamide derivatives stably interacted with the HDAC1 active site in both parasites as hypothesized.	benzamide	67-76	histone deacetylase 1	Homo sapiens	116-121
33885193-2	2021	The methodology furnished a set of benzamide model compounds, including the two poly (ADP-ribose) polymerase (PARP) inhibitors niraparib and veliparib, in moderate to excellent radiochemical yields.	benzamide	35-44	poly(ADP-ribose) polymerase 1	Homo sapiens	80-108
33885193-2	2021	The methodology furnished a set of benzamide model compounds, including the two poly (ADP-ribose) polymerase (PARP) inhibitors niraparib and veliparib, in moderate to excellent radiochemical yields.	benzamide	35-44	poly(ADP-ribose) polymerase 1	Homo sapiens	110-114
33671108-0	2021	The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter.	benzamide	10-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	133-138
33671108-3	2021	In this study, we determined the efficacy of the novel benzamide derivative, VKNG-2, to overcome MDR due to the overexpression of the ABCG2 transporter in the colon cancer cell line, S1-M1-80.	benzamide	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	134-139
33339666-0	2021	Synthesis, crystal structure and Hirshfeld Surface analysis of benzamide derivatives of thiourea as potent inhibitors of alpha-glucosidase in-vitro.	benzamide	63-72	sucrase isomaltase (alpha-glucosidase)	Mus musculus	121-138
33339666-1	2021	Benzamide based structural analogues 1-15 were synthesized, and evaluated for alpha-glucosidase inhibition activity in vitro for the first time.	benzamide	0-9	sucrase isomaltase (alpha-glucosidase)	Mus musculus	78-95
32416556-0	2020	Corrigendum to "Optimization of the benzamide fragment targeting the S2" site leads to potent dipeptidyl Peptidase-IV inhibitors" [Bioorg.	benzamide	36-45	dipeptidyl peptidase 4	Homo sapiens	94-117
33335670-0	2020	Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.	benzamide	83-92	histone deacetylase 3	Homo sapiens	41-46
33488256-0	2020	Synthesis and pharmacological effects of novel benzenesulfonamides carrying benzamide moiety as carbonic anhydrase and acetylcholinesterase inhibitors.	benzamide	76-85	acetylcholinesterase (Cartwright blood group)	Homo sapiens	119-139
32653824-1	2020	Though it has been demonstrated that Chidamide (CS055/HBI-8000), a novel benzamide class of histone deacetylase (HDAC) subtype-selectively inhibitor, reveals better anticancer effect in acute leukemia, but it remains unknown about the precise mechanism of Chidamide-induced acute leukemia cell apoptosis due to the lack of in situ molecular changes information.	benzamide	73-82	histone deacetylase 9	Homo sapiens	92-111
32653824-1	2020	Though it has been demonstrated that Chidamide (CS055/HBI-8000), a novel benzamide class of histone deacetylase (HDAC) subtype-selectively inhibitor, reveals better anticancer effect in acute leukemia, but it remains unknown about the precise mechanism of Chidamide-induced acute leukemia cell apoptosis due to the lack of in situ molecular changes information.	benzamide	73-82	histone deacetylase 9	Homo sapiens	113-117
33102692-0	2020	FOXA1 Regulation Turns Benzamide HDACi Treatment Effect-Specific in BC, Promoting NIS Gene-Mediated Targeted Radioiodine Therapy.	benzamide	23-32	forkhead box A1	Homo sapiens	0-5
32325365-0	2020	Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.	benzamide	60-69	histone deacetylase 9	Homo sapiens	79-83
31963723-0	2020	Profiling the Structural Determinants of Aryl Benzamide Derivatives as Negative Allosteric Modulators of mGluR5 by In Silico Study.	benzamide	41-55	glutamate receptor, ionotropic, kainate 1	Mus musculus	105-111
31910010-3	2020	Structure-activity relationship-driven expansion of a fragment hit led to discovery of dual MNK1 and MNK2 inhibitors based on a novel pyridine-benzamide scaffold.	benzamide	134-152	MAPK interacting serine/threonine kinase 1	Homo sapiens	92-96
31910010-3	2020	Structure-activity relationship-driven expansion of a fragment hit led to discovery of dual MNK1 and MNK2 inhibitors based on a novel pyridine-benzamide scaffold.	benzamide	134-152	MAPK interacting serine/threonine kinase 2	Homo sapiens	101-105
31963723-2	2020	At present, to explore the structural features of 106 newly synthesized aryl benzamide series molecules as mGluR5 NAMs, a set of ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses were firstly carried out applying comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) methods.	benzamide	72-86	glutamate receptor, ionotropic, kainate 1	Mus musculus	107-113
31963723-5	2020	Moreover, we found that aryl benzamide series molecules bind as mGluR5 NAMs at Site 1, which consists of amino acids Pro655, Tyr659, Ile625, Ile651, Ile944, Ser658, Ser654, Ser969, Ser965, Ala970, Ala973, Trp945, Phe948, Pro903, Asn907, Val966, Leu904, and Met962.	benzamide	24-38	glutamate receptor, ionotropic, kainate 1	Mus musculus	64-70
31963723-5	2020	Moreover, we found that aryl benzamide series molecules bind as mGluR5 NAMs at Site 1, which consists of amino acids Pro655, Tyr659, Ile625, Ile651, Ile944, Ser658, Ser654, Ser969, Ser965, Ala970, Ala973, Trp945, Phe948, Pro903, Asn907, Val966, Leu904, and Met962.	benzamide	24-38	interferon epsilon	Homo sapiens	117-123
31640932-0	2020	Optimization of the benzamide fragment targeting the S2" site leads to potent dipeptidyl peptidase-IV inhibitors.	benzamide	20-29	dipeptidyl peptidase 4	Homo sapiens	78-101
31670334-0	2019	Cp*CoIII-catalyzed formal [4+2] cycloaddition of benzamides to afford quinazolinone derivatives.	benzamide	49-59	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	3-8
31169043-0	2019	Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysis.	benzamide	40-49	glutathione S-transferase pi 1	Homo sapiens	86-93
31670334-1	2019	A Cp*CoIII-catalyzed arene C-H bond amidation/annulation of benzamides was developed to afford quinazolinone derivatives in one-pot with high yields and broad substrate scope.	benzamide	60-70	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	5-10
31378596-0	2019	Microwave-Assisted Organic Synthesis, structure-activity relationship, kinetics and molecular docking studies of non-cytotoxic benzamide derivatives as selective butyrylcholinesterase inhibitors.	benzamide	127-136	butyrylcholinesterase	Homo sapiens	162-183
31439379-0	2019	Design, synthesis and biological evaluation of benzamide derivatives as novel NTCP inhibitors that induce apoptosis in HepG2 cells.	benzamide	47-56	solute carrier family 10 member 1	Homo sapiens	78-82
31933782-1	2019	OBJECTIVE: To study the function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells by poly ADP-ribose polymerase-1 (PARP-1) inhibitor 3-amion benzamide (3-AB) onBRCA mutant and non-mutant breast cancer cells.	benzamide	190-207	poly(ADP-ribose) polymerase 1	Homo sapiens	59-65
31933782-1	2019	OBJECTIVE: To study the function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells by poly ADP-ribose polymerase-1 (PARP-1) inhibitor 3-amion benzamide (3-AB) onBRCA mutant and non-mutant breast cancer cells.	benzamide	190-207	BRCA1 DNA repair associated	Homo sapiens	70-74
31933782-1	2019	OBJECTIVE: To study the function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells by poly ADP-ribose polymerase-1 (PARP-1) inhibitor 3-amion benzamide (3-AB) onBRCA mutant and non-mutant breast cancer cells.	benzamide	190-207	poly(ADP-ribose) polymerase 1	Homo sapiens	142-170
31933782-1	2019	OBJECTIVE: To study the function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells by poly ADP-ribose polymerase-1 (PARP-1) inhibitor 3-amion benzamide (3-AB) onBRCA mutant and non-mutant breast cancer cells.	benzamide	190-207	poly(ADP-ribose) polymerase 1	Homo sapiens	172-178
31933782-1	2019	OBJECTIVE: To study the function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells by poly ADP-ribose polymerase-1 (PARP-1) inhibitor 3-amion benzamide (3-AB) onBRCA mutant and non-mutant breast cancer cells.	benzamide	209-213	poly(ADP-ribose) polymerase 1	Homo sapiens	59-65
31933782-1	2019	OBJECTIVE: To study the function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells by poly ADP-ribose polymerase-1 (PARP-1) inhibitor 3-amion benzamide (3-AB) onBRCA mutant and non-mutant breast cancer cells.	benzamide	209-213	BRCA1 DNA repair associated	Homo sapiens	70-74
31933782-1	2019	OBJECTIVE: To study the function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells by poly ADP-ribose polymerase-1 (PARP-1) inhibitor 3-amion benzamide (3-AB) onBRCA mutant and non-mutant breast cancer cells.	benzamide	209-213	poly(ADP-ribose) polymerase 1	Homo sapiens	142-170
31933782-1	2019	OBJECTIVE: To study the function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells by poly ADP-ribose polymerase-1 (PARP-1) inhibitor 3-amion benzamide (3-AB) onBRCA mutant and non-mutant breast cancer cells.	benzamide	209-213	poly(ADP-ribose) polymerase 1	Homo sapiens	172-178
31378596-1	2019	A series of benzamide derivatives 1-12 with various functional groups (-H, -Br, -F, -OCH3, -OC2H5, and -NO2) was synthesized using an economic, and facile Microwave-Assisted Organic Synthesis, and evaluated for acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE) activity in vitro.	benzamide	12-21	acetylcholinesterase (Cartwright blood group)	Homo sapiens	211-231
31327679-1	2019	For the purpose of synthesizing drug candidates with desirable bioactivity, a class of benzoyl amide containing nitrogen heterocyclic ring derivatives targeting VEGFR-2 was designed and screened out using Discovery Studio.	benzamide	87-100	kinase insert domain receptor	Homo sapiens	161-168
31378596-1	2019	A series of benzamide derivatives 1-12 with various functional groups (-H, -Br, -F, -OCH3, -OC2H5, and -NO2) was synthesized using an economic, and facile Microwave-Assisted Organic Synthesis, and evaluated for acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE) activity in vitro.	benzamide	12-21	acetylcholinesterase (Cartwright blood group)	Homo sapiens	233-237
31378596-1	2019	A series of benzamide derivatives 1-12 with various functional groups (-H, -Br, -F, -OCH3, -OC2H5, and -NO2) was synthesized using an economic, and facile Microwave-Assisted Organic Synthesis, and evaluated for acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE) activity in vitro.	benzamide	12-21	butyrylcholinesterase	Homo sapiens	243-264
31378596-1	2019	A series of benzamide derivatives 1-12 with various functional groups (-H, -Br, -F, -OCH3, -OC2H5, and -NO2) was synthesized using an economic, and facile Microwave-Assisted Organic Synthesis, and evaluated for acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE) activity in vitro.	benzamide	12-21	butyrylcholinesterase	Homo sapiens	266-270
30179749-0	2018	HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.	benzamide	69-78	histone deacetylase 3	Homo sapiens	0-5
31327679-0	2019	Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors.	benzamide	44-57	kinase insert domain receptor	Homo sapiens	121-128
30826710-2	2019	In the present study, a series of heteroaryl benzamide derivatives were selected as potent inhibitors against InhA, and their binding properties with InhA were investigated at atomic and electronic levels by ab initio molecular simulations based on protein-ligand docking, classical molecular mechanics optimizations and ab initio fragment molecular orbital (FMO) calculations.	benzamide	45-54	inhibin subunit alpha	Homo sapiens	110-114
30826710-2	2019	In the present study, a series of heteroaryl benzamide derivatives were selected as potent inhibitors against InhA, and their binding properties with InhA were investigated at atomic and electronic levels by ab initio molecular simulations based on protein-ligand docking, classical molecular mechanics optimizations and ab initio fragment molecular orbital (FMO) calculations.	benzamide	45-54	inhibin subunit alpha	Homo sapiens	150-154
30826710-4	2019	These findings provide informative structural concepts for designing novel heteroaryl benzamide derivatives with higher binding affinity to InhA.	benzamide	86-95	inhibin subunit alpha	Homo sapiens	140-144
30702760-1	2019	A series of benzamide derivatives possessing potent dopamine D2 , serotonin 5-HT1A , and 5-HT2A receptor properties were synthesized and evaluated as potential antipsychotics.	benzamide	12-21	5-hydroxytryptamine receptor 1A	Homo sapiens	76-82
30702760-1	2019	A series of benzamide derivatives possessing potent dopamine D2 , serotonin 5-HT1A , and 5-HT2A receptor properties were synthesized and evaluated as potential antipsychotics.	benzamide	12-21	5-hydroxytryptamine receptor 2A	Homo sapiens	91-95
30735902-9	2019	In this review, detail chemico-biological and structural information of HDAC3 in memory and learning functions and benzamide-based HDAC3 inhibitors has been focussed.	benzamide	115-124	histone deacetylase 3	Homo sapiens	131-136
30735902-10	2019	This may help to achieve a deep insight so that potent and selective benzamide-based HDAC3 inhibitors may be designed in future to combat memory and learning-related dysfunctions.	benzamide	69-78	histone deacetylase 3	Homo sapiens	85-90
30354009-9	2019	We proposed various chemical scaffolds including benzamide, carboxamide, and methyl benzimidazole targeting Akt2 and thus may act as potential leads for the further development of new anticancer agents.	benzamide	49-58	AKT serine/threonine kinase 2	Homo sapiens	108-112
29166796-0	2018	Structure-activity relationship investigation of benzamide and picolinamide derivatives containing dimethylamine side chain as acetylcholinesterase inhibitors.	benzamide	49-58	acetylcholinesterase (Cartwright blood group)	Homo sapiens	127-147
30351001-3	2018	In this study, inspired by the conclusion that ligand-induced "Phe199 shift" effect is the structural basis of Grp94-selective inhibition, a series of novel Grp94 selective inhibitors incorporating "benzamide" moiety were developed, among which compound 54 manifested the most potent Grp94 inhibitory activity with an IC50 value of 2 nM and over 1000-fold selectivity to Grp94 against Hsp90alpha.	benzamide	199-208	heat shock protein 90, beta (Grp94), member 1	Mus musculus	111-116
30351001-3	2018	In this study, inspired by the conclusion that ligand-induced "Phe199 shift" effect is the structural basis of Grp94-selective inhibition, a series of novel Grp94 selective inhibitors incorporating "benzamide" moiety were developed, among which compound 54 manifested the most potent Grp94 inhibitory activity with an IC50 value of 2 nM and over 1000-fold selectivity to Grp94 against Hsp90alpha.	benzamide	199-208	heat shock protein 90, beta (Grp94), member 1	Mus musculus	157-162
30351001-3	2018	In this study, inspired by the conclusion that ligand-induced "Phe199 shift" effect is the structural basis of Grp94-selective inhibition, a series of novel Grp94 selective inhibitors incorporating "benzamide" moiety were developed, among which compound 54 manifested the most potent Grp94 inhibitory activity with an IC50 value of 2 nM and over 1000-fold selectivity to Grp94 against Hsp90alpha.	benzamide	199-208	heat shock protein 90, beta (Grp94), member 1	Mus musculus	157-162
30351001-3	2018	In this study, inspired by the conclusion that ligand-induced "Phe199 shift" effect is the structural basis of Grp94-selective inhibition, a series of novel Grp94 selective inhibitors incorporating "benzamide" moiety were developed, among which compound 54 manifested the most potent Grp94 inhibitory activity with an IC50 value of 2 nM and over 1000-fold selectivity to Grp94 against Hsp90alpha.	benzamide	199-208	heat shock protein 90, beta (Grp94), member 1	Mus musculus	157-162
29935282-0	2018	A novel benzamide derivative protects ligature-induced alveolar bone erosion by inhibiting NFATc1-mediated osteoclastogenesis.	benzamide	8-17	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	91-97
30179749-8	2018	However, the importance of spiro hydrophobic cap group, as well as electron withdrawing fluorine group at the benzamide scaffold, should be well-accounted for retaining higher HDAC3 selectivity over HDAC1.	benzamide	110-119	histone deacetylase 1	Homo sapiens	199-204
30179749-10	2018	This detailed structural exploration will surely unveil a new vista of designing highly potent and selective benzamide-based HDAC3 inhibitors that may be a crucial weapon to battle against a variety of cancers.	benzamide	109-118	histone deacetylase 3	Homo sapiens	125-130
31330099-4	2019	Hydroxamic-acid-based inhibitors of HDACs 1-3, reported to have fast-on/fast-off binding kinetics, induce increased expression of PGRN in human neuronal models, while the benzamide class of slow-binding HDAC inhibitors does not produce this effect.	benzamide	171-180	histone deacetylase 1	Homo sapiens	36-45
31330099-4	2019	Hydroxamic-acid-based inhibitors of HDACs 1-3, reported to have fast-on/fast-off binding kinetics, induce increased expression of PGRN in human neuronal models, while the benzamide class of slow-binding HDAC inhibitors does not produce this effect.	benzamide	171-180	histone deacetylase 9	Homo sapiens	36-40
30044204-1	2019	The work presented here explores the structural and physicochemical features important for benzamide-based HDAC3 inhibitors to get an idea about the design aspect of potential inhibitors.	benzamide	91-100	histone deacetylase 3	Homo sapiens	107-112
30044204-2	2019	A number of molecular modeling studies (3D-QSAR CoMFA and CoMSIA, Bayesian classification modeling) were performed on 113 diverse set of benzamide-based HDAC3 inhibitors.	benzamide	137-146	histone deacetylase 3	Homo sapiens	153-158
30179749-0	2018	HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.	benzamide	69-78	histone deacetylase 3	Homo sapiens	95-100
30179749-0	2018	HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.	benzamide	69-78	sarcosine dehydrogenase	Homo sapiens	132-135
30179749-4	2018	Nowadays, compounds comprising benzamide functionality as zinc binding group (ZBG) have been emerged out to be highly effective and selective HDAC3 inhibitors.	benzamide	31-40	histone deacetylase 3	Homo sapiens	142-147
30179749-5	2018	In this article, QSAR and QAAR studies have been conducted on diverse benzamide-derived HDAC3 inhibitors as the first initiative to explore the designing strategies of higher active and selective HDAC3 inhibitors over HDAC1 and HDAC2.	benzamide	70-79	histone deacetylase 3	Homo sapiens	88-93
30179749-5	2018	In this article, QSAR and QAAR studies have been conducted on diverse benzamide-derived HDAC3 inhibitors as the first initiative to explore the designing strategies of higher active and selective HDAC3 inhibitors over HDAC1 and HDAC2.	benzamide	70-79	histone deacetylase 3	Homo sapiens	196-201
30179749-5	2018	In this article, QSAR and QAAR studies have been conducted on diverse benzamide-derived HDAC3 inhibitors as the first initiative to explore the designing strategies of higher active and selective HDAC3 inhibitors over HDAC1 and HDAC2.	benzamide	70-79	histone deacetylase 1	Homo sapiens	218-223
30179749-5	2018	In this article, QSAR and QAAR studies have been conducted on diverse benzamide-derived HDAC3 inhibitors as the first initiative to explore the designing strategies of higher active and selective HDAC3 inhibitors over HDAC1 and HDAC2.	benzamide	70-79	histone deacetylase 2	Homo sapiens	228-233
30179749-7	2018	QAAR models reflect that modification/substitution at the benzamide scaffold should be optimized in such a way so that these molecules possess lower steric bulk along with nonpolar features for achieving higher HDAC3 selectivity over HDAC1 and HDAC2.	benzamide	58-67	histone deacetylase 3	Homo sapiens	211-216
30179749-7	2018	QAAR models reflect that modification/substitution at the benzamide scaffold should be optimized in such a way so that these molecules possess lower steric bulk along with nonpolar features for achieving higher HDAC3 selectivity over HDAC1 and HDAC2.	benzamide	58-67	histone deacetylase 1	Homo sapiens	234-239
30179749-7	2018	QAAR models reflect that modification/substitution at the benzamide scaffold should be optimized in such a way so that these molecules possess lower steric bulk along with nonpolar features for achieving higher HDAC3 selectivity over HDAC1 and HDAC2.	benzamide	58-67	histone deacetylase 2	Homo sapiens	244-249
30179749-8	2018	However, the importance of spiro hydrophobic cap group, as well as electron withdrawing fluorine group at the benzamide scaffold, should be well-accounted for retaining higher HDAC3 selectivity over HDAC1.	benzamide	110-119	histone deacetylase 3	Homo sapiens	176-181
29853338-4	2018	In this article, 24 benzamide derivatives were designed, synthesized and investigated for the inhibition activity against CDK2.	benzamide	20-29	cyclin dependent kinase 2	Homo sapiens	122-126
29301237-0	2017	Synthesis and Smo Activity of Some Novel Benzamide Derivatives.	benzamide	41-50	smoothened, frizzled class receptor	Homo sapiens	14-17
29862624-1	2018	By making use of a dual-chelation-assisted strategy, a completely regiocontrolled oxidative C-H/C-H cross-coupling reaction between an N-acylaniline and a benzamide has been accomplished for the first time.	benzamide	155-164	churchill domain containing 1	Homo sapiens	92-99
29953251-6	2018	The hydrophobic aryl cap function is important for HDAC8 inhibition whereas benzamide moiety shows a negative impact on HDAC8 inhibition.	benzamide	76-85	histone deacetylase 8	Homo sapiens	120-125
29206502-6	2017	In conclusion, it is observed that the lead compounds #2 and #5 possessed inhibitory activity on the hGSTP1-1 by binding to the H-site as a substrate in which the para position of the phenyl ring of the benzamide moiety on the benzothiazole ring is important.	benzamide	203-212	glutathione S-transferase pi 1	Homo sapiens	101-109
28916341-0	2017	Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.	benzamide	47-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	120-124
28916341-3	2017	A series of 31 benzamide and phenyltetrazole derivatives with amide and urea linkers has been synthesized to serve as potential BCRP inhibitors in order to overcome BCRP-mediated MDR.	benzamide	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	128-132
28916341-3	2017	A series of 31 benzamide and phenyltetrazole derivatives with amide and urea linkers has been synthesized to serve as potential BCRP inhibitors in order to overcome BCRP-mediated MDR.	benzamide	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	165-169
28756263-6	2017	Among them, compounds 7i, w, y with Cl, CN or NO2 groups at the 4-position of the benzamide scaffold showed excellent affinity for S1R (Ki = 1.2-3.6 nM), selectivity for S2R (Ki up to 1400 nM) and high selectivity index (IC50(SY5Y)/Ki(S1R) ratio from 28 000 to 83 000).	benzamide	82-91	transmembrane BAX inhibitor motif containing 4	Homo sapiens	131-134
28807572-2	2017	Further derivatization of the prototype dual orexin receptor 1/2 antagonist lead (1) by installing a (S)-methyl group into the ethyl linker moiety between the pyrazole ring and benzamide resulted in an increase of the antagonist potency against orexin receptor 1/2 receptors.	benzamide	177-186	hypocretin receptor 1	Homo sapiens	45-62
28807572-2	2017	Further derivatization of the prototype dual orexin receptor 1/2 antagonist lead (1) by installing a (S)-methyl group into the ethyl linker moiety between the pyrazole ring and benzamide resulted in an increase of the antagonist potency against orexin receptor 1/2 receptors.	benzamide	177-186	hypocretin receptor 1	Homo sapiens	45-64
29103972-1	2017	Optimization of benzamide PPARdelta modulator 1 led to (E)-6-(2-((4-(furan-2-yl)-N-methylbenzamido)methyl)phenoxy)-4-methylhex-4-enoic acid (18), a potent selective PPARdelta modulator with significantly improved exposure in multiple species following oral administration.	benzamide	16-25	peroxisome proliferator activated receptor delta	Homo sapiens	26-35
29103972-1	2017	Optimization of benzamide PPARdelta modulator 1 led to (E)-6-(2-((4-(furan-2-yl)-N-methylbenzamido)methyl)phenoxy)-4-methylhex-4-enoic acid (18), a potent selective PPARdelta modulator with significantly improved exposure in multiple species following oral administration.	benzamide	16-25	peroxisome proliferator activated receptor delta	Homo sapiens	165-174
28756263-6	2017	Among them, compounds 7i, w, y with Cl, CN or NO2 groups at the 4-position of the benzamide scaffold showed excellent affinity for S1R (Ki = 1.2-3.6 nM), selectivity for S2R (Ki up to 1400 nM) and high selectivity index (IC50(SY5Y)/Ki(S1R) ratio from 28 000 to 83 000).	benzamide	82-91	transmembrane BAX inhibitor motif containing 4	Homo sapiens	235-238
28415009-6	2017	Further modification of benzamide 3, 11a and 19 afforded new thienyl and phenyl compounds (50a, 50b, 63a, 63b and 63c) with dramatic HDAC1 and HDAC2 dual selectivity, and the fluorine containing compound 56, with moderate HDAC3 selectivity.	benzamide	24-33	histone deacetylase 1	Homo sapiens	133-138
28415009-6	2017	Further modification of benzamide 3, 11a and 19 afforded new thienyl and phenyl compounds (50a, 50b, 63a, 63b and 63c) with dramatic HDAC1 and HDAC2 dual selectivity, and the fluorine containing compound 56, with moderate HDAC3 selectivity.	benzamide	24-33	histone deacetylase 2	Homo sapiens	143-148
27250763-3	2016	4SC-202, a novel oral benzamide type HDAC inhibitor (HDACi) specific for class I HDACs HDAC1, HDAC2 and HDAC3 and the histone demethylase LSD1, shows substantial anti-tumor activity in a broad range of cancer cell lines and xenograft tumor models.	benzamide	22-31	histone deacetylase 1	Homo sapiens	87-92
28174211-4	2017	For example, the benzamide class I HDAC-selective inhibitor, MGCD0103 [N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl] benzamide], was shown to block cardiac fibrosis, a process involving excess extracellular matrix deposition, which often results in heart dysfunction.	benzamide	17-26	histone deacetylase 9	Homo sapiens	35-39
28501514-0	2017	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.	benzamide	51-60	histone deacetylase 11	Homo sapiens	12-18
28175303-0	2016	Friedreich ataxia-induced pluripotent stem cell-derived neurons show a cellular phenotype that is corrected by a benzamide HDAC inhibitor.	benzamide	113-122	frataxin	Homo sapiens	0-17
27297568-0	2016	Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.	benzamide	0-9	cyclin dependent kinase 2	Homo sapiens	70-74
27548656-3	2016	Benzamide-substituted 2-pyridones are still by far the most popular selective EZH2 inhibitor class but alternative classes are now being reported.	benzamide	0-9	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	78-82
28175303-4	2016	Treatment with the benzamide HDAC inhibitor 109 significantly upregulated FXN expression and increased Fe-S and lipoic acid-containing protein levels, downregulated SOD2 levels, normalized LIP and ROS levels, and almost fully protected FRDA neurons from oxidative stress-mediated cell death.	benzamide	19-28	frataxin	Homo sapiens	74-77
28175303-4	2016	Treatment with the benzamide HDAC inhibitor 109 significantly upregulated FXN expression and increased Fe-S and lipoic acid-containing protein levels, downregulated SOD2 levels, normalized LIP and ROS levels, and almost fully protected FRDA neurons from oxidative stress-mediated cell death.	benzamide	19-28	superoxide dismutase 2	Homo sapiens	165-169
28175303-4	2016	Treatment with the benzamide HDAC inhibitor 109 significantly upregulated FXN expression and increased Fe-S and lipoic acid-containing protein levels, downregulated SOD2 levels, normalized LIP and ROS levels, and almost fully protected FRDA neurons from oxidative stress-mediated cell death.	benzamide	19-28	frataxin	Homo sapiens	236-240
27672541-3	2016	Chidamide (CS055) is a novel and orally active benzamide class of histone deacetylase (HDAC) inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, the enzymes that are involved and play an important role in tumor initiation and development in both tumor cells and their surrounding micro-environment.	benzamide	47-56	histone deacetylase 1	Homo sapiens	141-159
27208123-5	2016	The CDHB hydrolase (CbaA) was purified from strain DL-8, which can also hydrolyze 2-benzoxazolinone (BOA), 5-chloro-2-BOA, and benzamide.	benzamide	127-136	cadherin 12	Homo sapiens	4-8
26590100-1	2016	The paper will describe the synthesis and SAR studies that led to the discovery of benzamide (reverse amide) as potent and selective human beta3-adrenergic receptor agonist.	benzamide	83-92	adrenoceptor beta 3	Homo sapiens	139-164
26982372-3	2016	Linking benzamide substrates with a rotatable C-N bond, we constructed a novel semirigid pyramid-like scaffold that could support its two-turn alpha-helix mimicry without aromatic stacking interactions and could adopt the different dihedral angles of the key residues of p53 and BH3-only peptides.	benzamide	8-17	tumor protein p53	Homo sapiens	271-274
27508038-2	2016	Chidamide, a novel HDAC inhibitor of the benzamide class, is currently under clinical trials.	benzamide	41-50	histone deacetylase 9	Homo sapiens	19-23
27038494-0	2016	Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.	benzamide	51-60	matrix metallopeptidase 2	Homo sapiens	27-32
26731168-0	2016	Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists.	benzamide	0-9	histamine receptor H3	Homo sapiens	55-76
26536614-10	2016	The benzamide compound, NBBA, exhibited a potent anti-IL-6 activity with inhibition of 35.6 +- 0.5%, significantly different from in the LPS-induced HGFs (p < 0.001).	benzamide	4-13	interleukin 6	Homo sapiens	54-58
26613635-3	2015	The hybrids retained antiestrogenic and HDACi activity and, in the case of benzamide hybrids, were selective for Class I HDAC3 over Class II HDAC6.	benzamide	75-84	histone deacetylase 6	Homo sapiens	141-146
26337021-0	2015	Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists.	benzamide	71-80	nuclear receptor subfamily 1 group H member 4	Homo sapiens	102-122
26337021-0	2015	Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists.	benzamide	71-80	nuclear receptor subfamily 1 group H member 4	Homo sapiens	124-127
26337021-3	2015	The results turn out that replacing the 2,4-dichlorophenyl with 2,6-dichloro-4-amidophenyl shows great improvement in potency, replacing the benzoate with benzamide shows improvement in stability and slight declining of potency and 3-(tert-butyl)-4-hydroxyphenyl unit is essential in obtaining the FXR antagonistic activity.	benzamide	155-164	nuclear receptor subfamily 1 group H member 4	Homo sapiens	298-301
25981685-3	2015	Judicious selection of the substituents on the pyridine ring and benzamide groups led to 6b; which was highly potent, OX2R selective, and exhibited excellent development properties.	benzamide	65-74	hypocretin receptor 2	Homo sapiens	118-122
25768700-2	2015	The evaluation of the regioisomers 11a-j highlighted a net increase of the anti-LSD1 potency by shifting the benzamide moiety from ortho to meta and mainly to para position of tranylcypromine phenyl ring, independently from their trans or cis stereochemistry.	benzamide	109-118	lysine (K)-specific demethylase 1A	Mus musculus	80-84